<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Stripes × Isomorphic Labs</title>
<link href="https://fonts.googleapis.com/css2?family=Roboto:wght@100;300;400;500;700&family=JetBrains+Mono:wght@400;500&display=swap" rel="stylesheet">
<script type="module" src="https://ajax.googleapis.com/ajax/libs/model-viewer/3.5.0/model-viewer.min.js"></script>
<style>
/* ══ CUSTOM FONTS ══ */
@font-face{font-family:"Lutz Stripes Web";src:url("_Fonts/LutzStripesWeb-Regular.woff2") format("woff2"),url("_Fonts/LutzStripesWeb-Regular.woff") format("woff");font-display:swap}
@font-face{font-family:'Graphik Web';src:url('_Fonts/Graphik-Bold-Web.woff2') format('woff2'),url('_Fonts/Graphik-Bold-Web.woff') format('woff');font-weight:700;font-style:normal;font-display:swap}

*,*::before,*::after{margin:0;padding:0;box-sizing:border-box}
:root{
--bg:#F6F6F6;--bg2:#F0F0F0;--bg3:#F2F2F2;--bg4:#EAEAEA;
--text:#212121;--text2:#555555;--text3:#999999;
--accent:#635BFF;--accent2:#80E9FF;--green:#24D164;--pink:#FF5CAA;--orange:#FF7A00;--red:#FF4D6D;
--border:#dddedb;
--font-d:'Lutz Stripes Web','Roboto',sans-serif;
--font-b:'Roboto',system-ui,sans-serif;
--font-m:'JetBrains Mono',monospace;
--font-l:'Lutz Stripes Web','Roboto',system-ui,sans-serif;
--font-g:'Roboto',system-ui,sans-serif;
}
html{scrollbar-width:thin;scrollbar-color:#ccc transparent}
body{font-family:var(--font-b);background:var(--bg);color:var(--text);overflow:hidden;-webkit-font-smoothing:antialiased;height:100vh}
::selection{background:var(--accent);color:#fff}
::-webkit-scrollbar{width:5px}::-webkit-scrollbar-track{background:transparent}::-webkit-scrollbar-thumb{background:#ccc;border-radius:3px}

/* ══ LOADING SCREEN ══ */
#loader{position:fixed;inset:0;z-index:10000;background:linear-gradient(135deg,#eef6ef 0%,#eaf3f7 100%);display:flex;flex-direction:column;align-items:center;justify-content:center}
#loader.done{opacity:0;visibility:hidden;pointer-events:none;transition:opacity .6s ease 1s,visibility .6s ease 1s}
#loader model-viewer{background:transparent;--poster-color:transparent;transition:transform 1s cubic-bezier(.55,0,.2,1),opacity .8s ease}
#loader.done model-viewer{transform:scale(0);opacity:0}
#loader.done .loader-text{opacity:0;transition:opacity .4s ease}
#loader model-viewer::part(default-progress-bar){display:none}
.loader-text{font-family:var(--font-l);font-size:12px;color:var(--text3);letter-spacing:.15em;text-transform:uppercase}

/* ══ PASSWORD GATE ══ */
#pw-gate{position:fixed;inset:0;z-index:99999;background:linear-gradient(135deg,#eef6ef 0%,#eaf3f7 100%);display:flex;flex-direction:column;align-items:center;justify-content:center;gap:20px;transition:opacity .6s ease,visibility .6s ease}
#pw-gate.unlocked{opacity:0;visibility:hidden;pointer-events:none}
#pw-gate .pw-brand{display:flex;align-items:center;justify-content:center;gap:12px;margin-bottom:16px}
.pw-x{font-family:var(--font-m);font-size:13px;color:var(--text3);font-weight:400}
#pw-gate .pw-label{font-family:var(--font-l);font-size:11px;color:var(--text3);letter-spacing:.15em;text-transform:uppercase}
#pw-gate .pw-input-wrap{display:flex;align-items:center;gap:8px}
#pw-gate input{font-family:var(--font-b);font-size:14px;padding:10px 16px;border:1px solid var(--border);border-radius:10px;outline:none;width:260px;background:#fff;transition:border-color .2s}
#pw-gate input:focus{border-color:var(--accent)}
#pw-gate input.pw-error{border-color:var(--red);animation:pw-shake .4s ease}
#pw-gate button{font-family:var(--font-b);font-size:13px;font-weight:500;padding:10px 20px;border:none;border-radius:10px;background:var(--text);color:#fff;cursor:pointer;transition:opacity .2s}
#pw-gate button:hover{opacity:.8}
@keyframes pw-shake{0%,100%{transform:translateX(0)}20%,60%{transform:translateX(-6px)}40%,80%{transform:translateX(6px)}}

/* ══ VIDEO BACKGROUND ══ */
#scene-container{position:fixed;inset:0;z-index:1;overflow:hidden;background:linear-gradient(135deg,#eef6ef 0%,#eaf3f7 100%)}
#scene-container video{position:absolute;bottom:0;right:0;width:100%;height:100%;object-fit:cover;object-position:bottom right;opacity:.9;transition:opacity .8s ease}
#scene-container.panel-open video{opacity:.5}
#video-overlay{position:absolute;inset:0;background:radial-gradient(ellipse at 80% 80%,transparent 40%,rgba(246,246,246,.4) 100%);transition:background .5s ease}
#scene-container.panel-open #video-overlay{background:radial-gradient(ellipse at 60% 70%,transparent 20%,rgba(246,246,246,.6) 100%)}

/* ══ BRANDING (inside nav card) ══ */
.brand-overlay{display:flex;align-items:center;gap:10px;font-size:13px;font-weight:300;letter-spacing:.02em;opacity:.7;transition:opacity .3s,transform .3s;padding:6px 10px 14px;margin-bottom:4px;border-bottom:1px solid var(--border);overflow:hidden;flex-shrink:0}
.brand-overlay:hover{opacity:1;transform:translateX(2px)}
.brand-overlay .iso-logo{flex-shrink:0}
.brand-overlay .x-mark{font-family:var(--font-m);font-size:12px;color:var(--text3)}
.iso-logo{display:inline-block;position:relative;vertical-align:middle}
.iso-logo svg.iso-frame{display:block;height:100%}
.iso-logo .iso-lottie{position:absolute;top:0;left:0;overflow:hidden}
.iso-logo .iso-lottie svg{display:block}

/* ══ BACK BUTTON ══ */
.back-btn{position:fixed;top:28px;left:400px;z-index:60;display:flex;align-items:center;gap:10px;background:#fff;border:1px solid var(--border);border-radius:12px;padding:10px 18px;cursor:pointer;color:var(--text);font-family:var(--font-m);font-size:11px;letter-spacing:.08em;text-transform:uppercase;opacity:0;visibility:hidden;transform:translateX(-20px);transition:all .4s cubic-bezier(.22,1,.36,1)}
.back-btn.visible{opacity:1;visibility:visible;transform:translateX(0)}
.back-btn:hover{background:#f8f8f8;border-color:#bbb}
.back-btn svg{width:16px;height:16px;stroke:var(--text);stroke-width:2;fill:none}

/* ══ CLUSTER NAV (right side in content view) ══ */
.cluster-nav{position:fixed;right:48px;top:50%;transform:translateY(-50%);z-index:60;display:flex;flex-direction:column;gap:8px;opacity:0;visibility:hidden;transition:all .4s .2s}
.cluster-nav.visible{opacity:1;visibility:visible}
.cluster-nav-dot{width:10px;height:10px;border-radius:50%;cursor:pointer;transition:all .3s;opacity:.4;border:2px solid transparent}
.cluster-nav-dot:hover{opacity:.7;transform:scale(1.3)}
.cluster-nav-dot.active{opacity:1;transform:scale(1.5);box-shadow:0 0 0 3px rgba(255,255,255,.9),0 0 8px rgba(0,0,0,.1)}
.cluster-nav-dot .cn-tip{position:absolute;right:calc(100% + 12px);top:50%;transform:translateY(-50%);font-family:var(--font-m);font-size:9px;color:var(--text2);white-space:nowrap;opacity:0;transition:opacity .2s;pointer-events:none;text-transform:uppercase;letter-spacing:.08em}
.cluster-nav-dot:hover .cn-tip{opacity:1}

/* ══ FOCUS STATES ══ */
.nav-item:focus-visible,.nav-section-title:focus-visible,.back-btn:focus-visible,.cluster-nav-dot:focus-visible,button:focus-visible{outline:2px solid var(--accent);outline-offset:2px;border-radius:8px}

/* ══ CONTENT PANEL SYSTEM (floating cards) ══ */
#content-panels{position:fixed;top:0;right:0;bottom:0;left:396px;z-index:50;pointer-events:none;padding:24px 32px 24px 0}
.content-panel{position:absolute;top:24px;right:32px;bottom:24px;left:0;overflow-y:auto;opacity:0;visibility:hidden;transform:translateX(40px);transition:opacity .5s cubic-bezier(.22,1,.36,1),transform .5s cubic-bezier(.22,1,.36,1),visibility .5s;background:#fff;border:1px solid var(--border);border-radius:20px;box-shadow:0 2px 8px rgba(0,0,0,.04);pointer-events:none;padding:0}
.content-panel.active{opacity:1;visibility:visible;transform:translateX(0);pointer-events:auto}
.panel-inner{max-width:960px;margin:0 auto;padding:60px 48px 80px}
.panel-color-bar{height:2px;width:100%;position:sticky;top:0;z-index:2;border-radius:20px 20px 0 0;box-shadow:none;opacity:.5}
.panel-breadcrumb{font-family:var(--font-m);font-size:10px;color:var(--text3);letter-spacing:.1em;text-transform:uppercase;margin-bottom:32px;display:flex;align-items:center;gap:8px}
.panel-breadcrumb .bc-sep{color:var(--text3);font-size:8px}

/* ══ TYPOGRAPHY ══ */
.label{font-family:var(--font-b);font-size:11px;font-weight:500;text-transform:uppercase;letter-spacing:.15em;color:var(--text3);margin-bottom:12px;display:flex;align-items:center;gap:8px}
.label::before{content:'';width:20px;height:1px;background:var(--text3)}
h2.sec-title{font-family:var(--font-b);font-size:clamp(32px,4vw,52px);line-height:1.1;letter-spacing:-.03em;margin-bottom:16px;font-weight:300}
.sec-sub{font-size:17px;color:var(--text2);line-height:1.6;max-width:640px;margin-bottom:48px}
.gradient-text{color:var(--text)}
.callout{font-family:var(--font-b);font-size:clamp(20px,2.5vw,28px);font-style:italic;color:var(--text2);line-height:1.5;border-left:3px solid var(--border);padding-left:24px;margin:40px 0}

/* ══ HERO PANEL ══ */
.hero-content{max-width:800px}
.hero-eyebrow{display:inline-flex;align-items:center;gap:10px;margin-bottom:32px}
.hero-eyebrow .x-mark{font-family:var(--font-m);font-size:14px;color:var(--text3);margin:0 4px}
.hero-content h1{font-family:var(--font-b);font-size:clamp(44px,6.5vw,88px);line-height:1.02;letter-spacing:-.04em;margin-bottom:20px;font-weight:300}
.hero-content>p{font-size:clamp(15px,1.4vw,19px);color:var(--text2);line-height:1.65;max-width:580px;margin-bottom:40px}
.hero-meta{display:flex;gap:40px;flex-wrap:wrap}
.hero-meta-item{display:flex;flex-direction:column;gap:2px}
.hero-meta-item .val{font-family:var(--font-b);font-size:28px;font-weight:700;color:var(--text)}
.hero-meta-item .lbl{font-family:var(--font-b);font-size:12px;font-weight:500;color:var(--text3);text-transform:uppercase;letter-spacing:.08em}

/* ══ LOGO ROW ══ */
.logo-row{display:flex;gap:32px;align-items:center;flex-wrap:wrap;margin:32px 0}
.logo-row .lr-item{display:flex;align-items:center;gap:8px;opacity:.55;transition:opacity .3s}
.logo-row .lr-item:hover{opacity:1}
.lr-icon{width:32px;height:32px;border-radius:7px;display:flex;align-items:center;justify-content:center;font-weight:800;font-size:11px;color:#fff;flex-shrink:0;overflow:hidden}
.lr-icon img{width:100%;height:100%;object-fit:contain;padding:3px}
.lr-icon.no-pad img{padding:0;object-fit:cover;border-radius:inherit}
.brand-logo{height:18px;vertical-align:middle}
.brand-logo-lg{height:28px;vertical-align:middle}

/* ══ DATA TABLE ══ */
.data-table-wrap{background:#fff;border:1px solid var(--border);border-radius:16px;overflow:hidden;margin:32px 0}
.data-table{width:100%;border-collapse:collapse;font-size:14px}
.data-table thead{background:#f8f8f8}
.data-table th{font-family:var(--font-b);padding:14px 20px;text-align:left;font-weight:500;font-size:11px;text-transform:uppercase;letter-spacing:.08em;color:var(--text3);border-bottom:1px solid var(--border)}
.data-table td{padding:14px 20px;border-bottom:1px solid var(--border);color:var(--text2);vertical-align:top}
.data-table tr:last-child td{border-bottom:none}
.data-table tr:hover td{background:#f8f8f8;transition:background .2s}
.data-table .em{color:var(--text);font-weight:600}
.data-table .hl{color:var(--accent);font-weight:700}
@media(max-width:768px){.data-table-wrap{overflow-x:auto}}

/* ══ STAT GRID ══ */
.stat-grid{display:grid;grid-template-columns:repeat(auto-fit,minmax(220px,1fr));gap:20px;margin:32px 0}
.stat-card{padding:28px;background:#fff;border:1px solid var(--border);border-radius:16px;position:relative;overflow:hidden;transition:all .35s cubic-bezier(.22,1,.36,1)}
.stat-card::before{display:none}
.stat-card:hover{transform:translateY(-2px);box-shadow:0 4px 12px rgba(0,0,0,.06);border-color:#bbb}
.stat-val{font-family:var(--font-b);font-size:42px;font-weight:300;line-height:1;color:var(--s-color,var(--text));margin-bottom:6px}
.stat-label{font-family:var(--font-b);font-size:13px;font-weight:500;margin-bottom:4px}
.stat-desc{font-size:12px;color:var(--text3);line-height:1.5}
.mini-bar{height:4px;background:rgba(0,0,0,.06);border-radius:2px;margin-top:12px;overflow:hidden}
.mini-bar-fill{height:100%;border-radius:2px;width:0;transition:width 1.2s cubic-bezier(.22,1,.36,1)}

/* ══ QUOTE CARDS ══ */
.quotes-grid{display:grid;grid-template-columns:repeat(auto-fit,minmax(320px,1fr));gap:24px}
.q-card{background:#fff;border:1px solid var(--border);border-radius:16px;padding:28px;transition:all .35s cubic-bezier(.22,1,.36,1);cursor:pointer}
.q-card:hover{border-color:#bbb;transform:translateY(-2px);box-shadow:0 4px 12px rgba(0,0,0,.06)}
.q-mark{font-family:Georgia,serif;font-size:56px;line-height:1;color:var(--text3);opacity:.15}
.q-text{font-size:14px;line-height:1.7;color:var(--text2);font-style:italic;margin:8px 0 20px}
.q-card .q-extra{max-height:0;overflow:hidden;transition:max-height .5s cubic-bezier(.22,1,.36,1);font-size:13px;color:var(--text3);line-height:1.6}
.q-card.expanded .q-extra{max-height:200px}
.q-author{display:flex;align-items:center;gap:10px;padding-top:16px;border-top:1px solid var(--border)}
.q-avatar{width:36px;height:36px;border-radius:8px;display:flex;align-items:center;justify-content:center;font-weight:700;font-size:12px;color:#fff;flex-shrink:0}
.q-info h4{font-size:13px;font-weight:600}.q-info p{font-size:11px;color:var(--text3)}

/* ══ THESIS BLOCK ══ */
.thesis-item{display:flex;gap:20px;padding:24px;background:#fff;border:1px solid var(--border);border-radius:14px;margin-bottom:16px;transition:all .4s cubic-bezier(.22,1,.36,1);cursor:pointer}
.thesis-item:hover{border-color:#bbb;background:#fafafa}
.thesis-num{width:40px;height:40px;border-radius:10px;background:#f2f2f2;display:flex;align-items:center;justify-content:center;font-family:var(--font-m);font-size:13px;font-weight:600;color:var(--text);flex-shrink:0}
.thesis-item h3{font-size:16px;font-weight:700;margin-bottom:4px;display:flex;align-items:center;gap:8px}
.thesis-item h3 .expand-icon{font-size:12px;color:var(--text3);transition:transform .3s}
.thesis-item.expanded h3 .expand-icon{transform:rotate(180deg)}
.thesis-item p{font-size:13px;color:var(--text2);line-height:1.65}
.thesis-item .thesis-extra{max-height:0;overflow:hidden;transition:max-height .5s cubic-bezier(.22,1,.36,1);font-size:13px;color:var(--text3);line-height:1.7;margin-top:0}
.thesis-item.expanded .thesis-extra{max-height:300px;margin-top:12px}

/* ══ PARTNER CARDS ══ */
.partner-grid{display:grid;grid-template-columns:repeat(auto-fit,minmax(300px,1fr));gap:24px;margin:32px 0}
.p-card{padding:28px;background:#fff;border:1px solid var(--border);border-radius:16px;transition:all .35s cubic-bezier(.22,1,.36,1);cursor:pointer}
.p-card:hover{border-color:#bbb;transform:translateY(-2px);box-shadow:0 4px 12px rgba(0,0,0,.06)}
.p-card-head{display:flex;align-items:center;gap:12px;margin-bottom:12px}
.p-card-head .lr-icon{width:44px;height:44px;border-radius:10px;font-size:15px}
.p-card-head .name{font-size:18px;font-weight:700}
.p-card .type{font-size:11px;text-transform:uppercase;letter-spacing:.1em;color:var(--text3);margin-bottom:8px}
.p-card .desc{font-size:13px;color:var(--text2);line-height:1.6}
.p-card .p-extra{max-height:0;overflow:hidden;transition:max-height .5s cubic-bezier(.22,1,.36,1);font-size:13px;color:var(--text3);line-height:1.6}
.p-card.expanded .p-extra{max-height:200px;margin-top:12px}

/* ══ RATING DOTS ══ */
.dots{display:flex;gap:3px}
.dot{width:16px;height:5px;border-radius:3px;background:rgba(0,0,0,.08)}
.dot.on{background:var(--text)}.dot.g{background:var(--green)}.dot.o{background:var(--orange)}

/* ══ SVG DONUT ══ */
.donut-chart{width:36px;height:36px;display:inline-block;vertical-align:middle}
.donut-chart circle{fill:none;stroke-width:3;stroke-linecap:round}
.donut-chart .donut-bg{stroke:rgba(0,0,0,.08)}
.donut-chart .donut-fill{stroke:var(--accent);stroke-dasharray:0 100;transition:stroke-dasharray 1.2s cubic-bezier(.22,1,.36,1)}

/* ══ BADGES ══ */
.badge{display:inline-block;padding:3px 10px;border-radius:100px;font-size:10px;font-weight:700;letter-spacing:.04em;text-transform:uppercase}
.badge-leader{background:rgba(36,209,100,.12);color:var(--green)}
.badge-contend{background:rgba(255,122,0,.12);color:var(--orange)}
.badge-emerge{background:rgba(128,233,255,.12);color:var(--accent2)}

/* ══ PIPELINE STAGE TAGS ══ */
.stage-tag{display:inline-block;padding:2px 8px;border-radius:100px;font-size:9px;font-weight:600;letter-spacing:.03em;white-space:nowrap}
.stage-disc{background:rgba(0,188,212,.10);color:#00838f}
.stage-tgtval{background:rgba(33,150,243,.10);color:#1565c0}
.stage-hit{background:rgba(156,39,176,.10);color:#7b1fa2}
.stage-lead{background:rgba(255,92,170,.10);color:#c2185b}
.stage-preclin{background:rgba(255,122,0,.10);color:#e65100}
.stage-clin{background:rgba(244,67,54,.10);color:#c62828}
.stage-infra{background:rgba(0,0,0,.05);color:var(--text3)}
.stage-e2e{background:rgba(36,209,100,.10);color:#2e7d32}

/* ══ RISK TABLE ══ */
.risk-row{display:grid;grid-template-columns:1fr 1fr;gap:0;border-bottom:1px solid var(--border)}
.risk-row:last-child{border-bottom:none}
.risk-cell{padding:20px 24px;font-size:13px;line-height:1.65;color:var(--text2)}
.risk-cell:first-child{border-right:1px solid var(--border);color:var(--red)}
.risk-cell strong{color:var(--text);font-weight:600;display:block;margin-bottom:4px}

/* ══ TEAM GRID ══ */
.team-grid{display:grid;grid-template-columns:repeat(auto-fit,minmax(240px,1fr));gap:24px;margin:32px 0}
.team-card{padding:24px;background:#fff;border:1px solid var(--border);border-radius:14px;transition:all .3s}
.team-card:hover{border-color:#bbb;transform:translateY(-2px)}
.team-card h4{font-size:14px;font-weight:700;margin-bottom:2px}
.team-card .role{font-size:12px;color:var(--text2);margin-bottom:8px}
.team-card p{font-size:12px;color:var(--text3);line-height:1.5}

/* ══ TIMELINE ══ */
.timeline{position:relative;padding-left:32px;margin:32px 0}
.timeline::before{content:'';position:absolute;left:8px;top:0;bottom:0;width:2px;background:var(--border)}
.timeline-item{position:relative;padding-bottom:28px;opacity:0;transform:translateX(-20px);transition:all .5s cubic-bezier(.22,1,.36,1)}
.timeline-item.tl-visible{opacity:1;transform:translateX(0)}
.timeline-item::before{content:'';position:absolute;left:-28px;top:4px;width:12px;height:12px;border-radius:50%;background:var(--text3);border:2px solid #fff;z-index:1}
.timeline-item .tl-date{font-family:var(--font-m);font-size:10px;color:var(--text3);letter-spacing:.1em;text-transform:uppercase;margin-bottom:4px}
.timeline-item h4{font-size:14px;font-weight:600;margin-bottom:2px}
.timeline-item p{font-size:12px;color:var(--text3);line-height:1.5}

/* ══ PIPELINE ══ */
.pipeline{display:flex;gap:0;margin:32px 0;overflow-x:auto;padding-bottom:8px}
.pipeline-stage{flex:1;min-width:160px;text-align:center;position:relative;padding:20px 12px}
.pipeline-stage::after{content:'';position:absolute;top:50%;right:0;width:100%;height:2px;background:var(--border);opacity:.5;z-index:0}
.pipeline-stage:last-child::after{display:none}
.pipeline-node{width:44px;height:44px;border-radius:50%;margin:0 auto 12px;display:flex;align-items:center;justify-content:center;font-family:var(--font-m);font-size:11px;font-weight:600;position:relative;z-index:1;border:2px solid var(--border);transition:all .4s}
.pipeline-stage.pl-active .pipeline-node{background:#f2f2f2;border-color:var(--text);box-shadow:none}
.pipeline-stage.pl-future .pipeline-node{opacity:.4;border-style:dashed}
.pipeline-stage h4{font-size:11px;font-weight:600;margin-bottom:4px}
.pipeline-stage p{font-size:10px;color:var(--text3);line-height:1.4}

/* ══ CTA ══ */
.cta-content{text-align:center;padding:60px 0}
.cta-content h2{font-family:var(--font-b);font-size:clamp(36px,5vw,60px);letter-spacing:-.03em;margin-bottom:16px;font-weight:300}
.cta-content p{font-size:17px;color:var(--text2);max-width:500px;margin:0 auto 20px}
.cta-footer{padding:40px 0;border-top:1px solid var(--border);font-size:12px;color:var(--text3);display:flex;justify-content:space-between;flex-wrap:wrap;gap:12px}

/* ══ NAVIGATION SIDEBAR ══ */
.deck-nav{position:fixed;left:50%;top:50%;transform:translate(-50%,-50%);z-index:30;
  width:340px;min-width:320px;max-height:calc(100vh - 80px);
  transition:left .5s cubic-bezier(.22,1,.36,1),top .5s cubic-bezier(.22,1,.36,1),transform .5s cubic-bezier(.22,1,.36,1),width .4s cubic-bezier(.22,1,.36,1),opacity .4s,visibility .4s}
.deck-nav.hidden{opacity:0;visibility:hidden;transform:translate(-50%,-50%) scale(.95)}
/* When panel is open, slide to left sidebar position */
.deck-nav.sidebar{left:28px;top:50%;transform:translateY(-50%);width:340px}
.deck-nav-inner{background:#fff;
  border:1px solid var(--border);border-radius:20px;padding:20px 20px;
  box-shadow:0 2px 8px rgba(0,0,0,.04);
  display:flex;flex-direction:column;gap:0;max-height:calc(100vh - 80px);overflow-y:auto;overflow-x:hidden}
.nav-section{min-width:0;border-bottom:1px solid var(--border);padding:4px 0}
.nav-section:last-child{border-bottom:none}
.nav-section-title{display:flex;align-items:center;gap:8px;padding:10px 12px;
  border-radius:10px;cursor:pointer;font-family:var(--font-b);font-size:13px;font-weight:500;
  color:var(--text);transition:background .2s;user-select:none}
.nav-section-title:hover{background:rgba(0,0,0,.05)}
.nav-section-icon{width:8px;height:8px;border-radius:50%;flex-shrink:0}
.nav-chevron{font-size:10px;color:var(--text3);margin-left:auto;transition:transform .3s}
.nav-section.expanded .nav-chevron{transform:rotate(180deg)}
.nav-section-items{max-height:0;overflow:hidden;transition:max-height .4s cubic-bezier(.22,1,.36,1)}
.nav-section.expanded .nav-section-items{max-height:300px}
.nav-item{display:block;width:100%;text-align:left;padding:7px 12px 7px 28px;
  background:none;border:none;font-family:var(--font-b);font-size:12px;font-weight:300;
  color:var(--text2);cursor:pointer;border-radius:8px;transition:all .2s;
  position:relative}
.nav-item::before{content:'';position:absolute;left:14px;top:50%;transform:translateY(-50%);
  width:5px;height:5px;border-radius:50%;background:var(--nav-accent,var(--accent));opacity:.5}
.nav-item:hover{background:rgba(0,0,0,.04);color:var(--text)}
.nav-item:hover::before{opacity:1}

/* ══ CUSTOM GRIDS (extracted from inline styles) ══ */
.scale-grid-3{display:grid;grid-template-columns:repeat(3,1fr)}
.scale-grid-2{display:grid;grid-template-columns:1fr 1fr}
.team-grid--ops{grid-template-columns:repeat(2,1fr)}
.partner-grid--single{grid-template-columns:1fr}
.council-grid{display:grid;grid-template-columns:1fr 1fr}

/* ══ RESPONSIVE — TABLET (1024px) ══ */
@media(max-width:1024px) and (min-width:769px){
  .deck-nav{width:320px}
  .deck-nav.sidebar{width:320px;left:16px}
  #content-panels{left:352px}
  .back-btn{left:356px}
  .panel-inner{padding:48px 32px 60px}
  .stat-val{font-size:36px}
  .stat-grid{grid-template-columns:repeat(auto-fit,minmax(180px,1fr))}
  .team-grid{grid-template-columns:repeat(auto-fit,minmax(200px,1fr))}
}

/* ══ RESPONSIVE — MOBILE (768px) ══ */
@media(max-width:768px){
  /* — Layout: Nav bottom sheet — */
  .deck-nav{left:0;right:0;bottom:0;top:auto;transform:none;width:100%;max-height:60vh;border-radius:0;z-index:100;transition:transform .4s cubic-bezier(.22,1,.36,1),opacity .3s}
  .deck-nav.hidden{transform:translateY(100%);opacity:0;visibility:hidden}
  .deck-nav.sidebar{left:0;top:auto;transform:translateY(100%);width:100%;opacity:0;pointer-events:none}
  .deck-nav-inner{border-radius:20px 20px 0 0;padding:8px 14px 14px;max-height:60vh}
  .deck-nav-inner::before{content:'';display:block;width:40px;height:4px;background:rgba(0,0,0,.15);border-radius:2px;margin:0 auto 10px}
  .brand-overlay{font-size:11px;padding:4px 10px 12px;margin-bottom:4px}
  .nav-section-title{font-size:12px;padding:10px 12px;min-height:44px;display:flex;align-items:center}
  .nav-item{font-size:11px;padding:10px 12px 10px 28px;min-height:44px;display:flex;align-items:center}
  .cluster-nav{display:none}

  /* — Layout: Full-screen panels — */
  #content-panels{left:0;right:0;top:0;bottom:0;padding:0;z-index:80}
  .content-panel{top:0;right:0;bottom:0;left:0;border-radius:0;border:none;overscroll-behavior-y:contain;-webkit-overflow-scrolling:touch}
  .panel-inner{padding:48px 16px 72px;max-width:100%}
  .back-btn{top:12px;left:12px;padding:10px 16px;min-height:44px;z-index:90;font-size:10px}

  /* — Typography — */
  .stat-val{font-size:32px}
  h2.sec-title{font-size:clamp(24px,6vw,34px)}
  .hero-content h1{font-size:clamp(34px,8vw,44px)}
  .callout{font-size:clamp(16px,3.5vw,20px);padding-left:16px;margin:24px 0}
  .q-mark{font-size:40px}
  .cta-content h2{font-size:clamp(28px,7vw,40px)}

  /* — Grids — */
  .hero-meta{gap:24px}
  .stat-grid{grid-template-columns:1fr 1fr}
  .partner-grid{grid-template-columns:1fr}
  .quotes-grid{grid-template-columns:1fr}
  .team-grid{grid-template-columns:1fr 1fr}
  .team-grid--ops{grid-template-columns:1fr}
  .scale-grid-3{grid-template-columns:1fr}
  .scale-grid-2{grid-template-columns:1fr}
  .council-grid{grid-template-columns:1fr}
  .risk-row{grid-template-columns:1fr}
  .risk-cell:first-child{border-right:none;border-bottom:1px solid var(--border)}
  .risk-cell{padding:14px 16px;font-size:12.5px}

  /* — Pipeline: vertical on mobile — */
  .pipeline{flex-direction:column;gap:0;align-items:stretch}
  .pipeline-stage{min-width:unset;text-align:left;padding:12px 16px;display:flex;align-items:center;gap:14px}
  .pipeline-stage::after{display:none}
  .pipeline-node{margin:0;flex-shrink:0}
  .pipeline-stage h4{font-size:13px}
  .pipeline-stage p{font-size:11px}

  /* — Tables: scroll hint shadows — */
  .data-table-wrap{overflow-x:auto;-webkit-overflow-scrolling:touch}
  .data-table th,.data-table td{padding:10px 14px;font-size:13px}
  .data-table th{font-size:10px;white-space:nowrap}
  .data-table th[style*="width"]{width:auto!important;min-width:120px}

  /* — Logo rows — */
  .logo-row{gap:16px}
  .logo-row .lr-item{gap:6px}

  /* — Video background — */
  #scene-container video{width:100vw;height:100vh;object-fit:cover;opacity:.6}
  #scene-container.panel-open video{opacity:0;visibility:hidden}

  /* — Loading screen — */
  #loader model-viewer{width:200px!important;height:200px!important}
  .loader-text{font-size:10px}
}

/* ══ RESPONSIVE — SMALL PHONE (380px) ══ */
@media(max-width:380px){
  .stat-grid{grid-template-columns:1fr}
  .team-grid{grid-template-columns:1fr}
  .stat-val{font-size:28px}
  .panel-inner{padding:40px 12px 60px}
  .hero-meta{flex-direction:column;gap:16px}
  .hero-content h1{font-size:32px}
  .data-table th,.data-table td{padding:8px 10px;font-size:12px}
}

/* ══ TOUCH DEVICES ══ */
@media(hover:none){
  .stat-card:hover,.q-card:hover,.thesis-item:hover,.p-card:hover,.team-card:hover{transform:none;background:transparent}
  .stat-card:active,.q-card:active,.thesis-item:active,.p-card:active,.team-card:active{transform:scale(.98);transition:transform .1s}
  .nav-item:hover{background:none}
  .nav-item:active{background:rgba(0,0,0,.06)}
  .nav-section-title:hover{background:none}
  .nav-section-title:active{background:rgba(0,0,0,.06)}
  .brand-overlay:hover{opacity:1;transform:none}
}

/* ══ ACCESSIBILITY ══ */
@media(prefers-reduced-motion:reduce){
  *,*::before,*::after{animation-duration:.01ms!important;animation-iteration-count:1!important;transition-duration:.01ms!important}
}
</style>
</head>
<body>

<!-- ══ PASSWORD GATE ══ -->
<div id="pw-gate">
  <div class="pw-brand">
    <img src="https://www.stripes.co/dist/svg/logo-black.svg" alt="Stripes" style="height:22px;opacity:.85" onerror="this.outerHTML='<span style=font-weight:800;letter-spacing:.05em;font-size:16px>///\\ STRIPES</span>'">
    <span class="pw-x">x</span>
    <span class="iso-logo" id="pw-iso-logo" style="height:30px">
      <svg class="iso-frame" viewBox="0 0 259 40" xmlns="http://www.w3.org/2000/svg"><path fill="#1E1E1E" d="M258.8,5.6v28.9c0,3.1-2.5,5.6-5.6,5.6h-64.1c-2.2,0-4.1-1.3-5-3.1c-0.9,1.9-2.8,3.1-5,3.1H45.5c-2.2,0-4.1-1.3-5-3.1c-0.9,1.8-2.8,3.1-5,3.1h-30C2.5,40,0,37.5,0,34.4V5.6C0,2.5,2.5,0,5.6,0h30c2.2,0,4.1,1.3,5,3.1c0.9-1.8,2.8-3.1,5-3.1h133.6c2.2,0,4.1,1.3,5,3.1c0.9-1.9,2.8-3.1,5-3.1h64.1C256.3,0,258.8,2.5,258.8,5.6L258.8,5.6zM40,34.4V5.6c0-2.5-2-4.4-4.4-4.4h-30c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.4,2,4.4,4.4,4.4h30C38,38.9,39.9,36.9,40,34.4zM183.6,34.4V5.6c0-2.4-2-4.4-4.4-4.4H45.5c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.5,2,4.4,4.4,4.4h133.6C181.6,38.9,183.6,36.9,183.6,34.4zM257.7,5.6c0-2.4-2-4.4-4.4-4.4h-64.1c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.4,2,4.4,4.4,4.4h64.1c2.4,0,4.4-2,4.4-4.4V5.6z"/><path fill="#1E1E1E" transform="translate(9.065,1.4) scale(0.93)" d="M52.3,28.1h2.5V9.5h-2.5V28.1zM65.9,21.2c-0.3-0.2-0.6-0.3-1-0.4c-0.4-0.1-1.1-0.3-2.3-0.6c-1.3-0.3-1.6-0.4-1.9-0.5c-0.8-0.3-1.1-0.7-1.1-1.4c0-1.2,1-2,2.6-2c1.6,0,3,0.8,3.7,2.2l1.7-1.3c-0.8-1.7-2.9-2.8-5.2-2.8c-1.5,0-2.6,0.4-3.6,1.2c-0.9,0.8-1.4,1.7-1.4,2.9c0,1.2,0.4,2.1,1.5,2.7c0.3,0.2,0.6,0.4,1.1,0.5c0.4,0.1,1.1,0.3,2,0.5c0.8,0.2,1.3,0.3,1.6,0.4c0.2,0.1,0.5,0.1,0.6,0.2c0.9,0.3,1.3,0.8,1.3,1.6c0,1.3-1.2,2.1-3,2.1s-3.4-1-4.1-2.5l-1.8,1.3c1,2,3.3,3.2,6,3.2c1.5,0,2.7-0.4,3.8-1.2c1-0.8,1.5-1.8,1.5-3.1C67.6,22.8,67.1,21.9,65.9,21.2zM80,16.4c1.1,1.2,1.6,3,1.6,4.9s-0.6,3.7-1.6,4.9c-1.1,1.3-2.8,2.1-4.7,2.1c-1.9,0-3.5-0.8-4.7-2.1c-1.1-1.2-1.6-3-1.6-4.9s0.6-3.7,1.6-4.9c1.1-1.3,2.8-2.1,4.7-2.1C77.2,14.3,78.9,15.1,80,16.4zM79.3,21.4c0-3.1-1.6-5.1-3.9-5.1c-2.4,0-3.9,2-3.9,5.1s1.6,5.1,3.9,5.1C77.8,26.4,79.3,24.5,79.3,21.4zM98.2,14.3c-1.8,0-3.4,0.9-4.3,2.3c-0.7-1.5-2-2.3-3.8-2.3c-1.7,0-3.1,0.8-3.9,2.1v-1.8h-2.3v13.5h2.3V20c0-1,0.3-1.8,0.9-2.5c0.6-0.6,1.5-1.1,2.3-1.1c1.7,0,2.7,1.2,2.7,3.3v8.3h2.3V20c0-1,0.3-1.8,0.9-2.5c0.6-0.6,1.5-1.1,2.3-1.1c1.7,0,2.7,1.2,2.7,3.3v8.3h2.3v-8.9C102.6,16.3,100.9,14.3,98.2,14.3zM115.6,16.4c1.1,1.2,1.6,3,1.6,4.9s-0.6,3.7-1.6,4.9c-1.1,1.3-2.8,2.1-4.7,2.1s-3.5-0.8-4.7-2.1c-1.1-1.2-1.6-3-1.6-4.9s0.6-3.7,1.6-4.9c1.1-1.3,2.8-2.1,4.7-2.1S114.5,15.1,115.6,16.4zM114.9,21.4c0-3.1-1.6-5.1-3.9-5.1c-2.4,0-3.9,2-3.9,5.1s1.6,5.1,3.9,5.1C113.4,26.4,114.9,24.5,114.9,21.4zM121.8,16.3v-1.7h-2.3v13.5h2.3v-7.4c0-1.2-0.1-2.5,0.6-3.2c0.5-0.5,0.9-0.6,1.9-0.6c0.4,0,2.1,0,2.1,0v-2.3h-2.2C123.7,14.6,122.4,14.8,121.8,16.3zM139.1,16.5c0.9,1.3,1.5,3,1.5,4.9s-0.5,3.6-1.5,4.9c-1.1,1.4-2.6,2.2-4.4,2.2c-1.8,0-3.4-0.8-4.2-2.3v6.6h-2.3V14.6h2.3v2c0.9-1.4,2.4-2.2,4.2-2.2C136.5,14.3,138.1,15.1,139.1,16.5zM138.2,21.4c0-3-1.5-5-4-5c-2.3,0-3.8,1.7-3.8,4.5v1c0,2.8,1.6,4.5,3.8,4.5C136.7,26.4,138.2,24.4,138.2,21.4zM149.1,14.3c-1.7,0-3.1,0.8-4,2.1V9.5h-2.3v18.6h2.3v-8.1c0-1,0.3-1.9,1-2.5c0.7-0.7,1.5-1,2.4-1c1.8,0,2.8,1.2,2.8,3.3v8.3h2.3v-8.9C153.6,16.2,151.9,14.3,149.1,14.3zM156.4,28.1h2.3V14.6h-2.3V28.1zM156.1,12.6h2.9v-3h-2.9V12.6zM167.4,26.4c-2.5,0-4.1-2-4.1-5s1.6-5,4.1-5c1.7,0,3,1,3.4,2.9l2-1c-0.7-2.4-2.7-3.9-5.4-3.9c-1.9,0-3.6,0.7-4.7,2.1c-1.1,1.3-1.7,3-1.7,5s0.6,3.7,1.7,5c1.1,1.3,2.8,2.1,4.7,2.1c2.7,0,4.7-1.6,5.4-4l-2.1-1C170.3,25.3,169.1,26.4,167.4,26.4zM198.6,9.5h-2.5v18.6h11.8V26h-9.3V9.5zM220.2,26.1h1.2v2h-2.8c-0.7,0-1.2-0.4-1.2-1.5c-0.9,1.1-2.6,1.8-4.4,1.8c-1.3,0-2.4-0.4-3.2-1.1c-0.8-0.7-1.2-1.7-1.2-2.8c0-2.3,1.5-3.7,5.1-4.4l3.3-0.7v-0.6c0-1.6-0.9-2.4-2.7-2.4c-1.7,0-2.7,0.8-3.1,2.3l-2.2-0.6c0.7-2.3,2.7-3.8,5.4-3.8c3.1,0,4.9,1.6,4.9,4.4v6.6C219.3,26,219.2,26.1,220.2,26.1zM217,21.2l-2.6,0.6c-2.6,0.5-3.5,1.3-3.5,2.6c0,1.3,0.9,2.1,2.4,2.1c1,0,1.9-0.3,2.6-0.8c0.7-0.6,1.1-1.3,1.1-2.1V21.2zM233.7,16.5c0.9,1.3,1.5,3,1.5,4.9s-0.5,3.6-1.5,4.9c-1.1,1.4-2.6,2.2-4.4,2.2s-3.4-0.8-4.2-2.3v2h-2.3V9.5h2.3v7c0.9-1.4,2.4-2.2,4.2-2.2C231.1,14.3,232.7,15.1,233.7,16.5zM232.8,21.4c0-3-1.5-5-4-5c-2.3,0-3.8,1.7-3.8,4.5v1c0,2.8,1.6,4.5,3.8,4.5C231.3,26.4,232.8,24.4,232.8,21.4zM245.5,21.2c-0.3-0.2-0.6-0.3-1-0.4c-0.4-0.1-1.1-0.3-2.3-0.6c-1.3-0.3-1.6-0.4-1.9-0.5c-0.8-0.3-1.1-0.7-1.1-1.4c0-1.2,1-2,2.6-2c1.6,0,3,0.8,3.7,2.2l1.7-1.3c-0.8-1.7-2.9-2.8-5.2-2.8c-1.4,0-2.6,0.4-3.6,1.2c-0.9,0.8-1.4,1.7-1.4,2.9c0,1.2,0.4,2.1,1.4,2.7c0.3,0.2,0.6,0.4,1.1,0.5c0.4,0.1,1.1,0.3,2,0.5c0.8,0.2,1.3,0.3,1.6,0.4c0.2,0.1,0.5,0.1,0.6,0.2c0.9,0.3,1.3,0.8,1.3,1.6c0,1.3-1.2,2.1-3,2.1c-1.8,0-3.4-1-4.1-2.5l-1.8,1.3c1,2,3.3,3.2,6,3.2c1.5,0,2.7-0.4,3.8-1.2c1-0.8,1.5-1.8,1.5-3.1C247.1,22.8,246.6,21.9,245.5,21.2z"/></svg>
      <span class="iso-lottie" data-iso-lottie style="width:15.4%;height:100%;border-radius:2px"></span>
    </span>
  </div>
  <div class="pw-label">Enter password to continue</div>
  <div class="pw-input-wrap">
    <input type="password" id="pw-input" placeholder="Password" autocomplete="off" autofocus>
    <button id="pw-btn">Enter</button>
  </div>
</div>

<!-- ══ LOADING SCREEN ══ -->
<div id="loader">
  <model-viewer
    src="https://cdn.prod.website-files.com/683d9417ea8f9b604314bfb1/686665832cdbbd365eb33fc0_ISOLVL2_SurfaceDna_glTF_09.gltf.txt"
    alt="Protein structure"
    camera-controls auto-rotate rotation-per-second="30deg"
    interaction-prompt="none" shadow-intensity="0"
    exposure="1.37" tone-mapping="neutral"
    style="width:280px;height:280px;--poster-color:transparent;background:transparent"
  ></model-viewer>
  <p class="loader-text" id="loaderText">Loading...</p>
</div>

<!-- ══ VIDEO BACKGROUND ══ -->
<div id="scene-container">
  <video id="bgVideo" autoplay muted loop playsinline preload="auto"></video>
  <div id="video-overlay"></div>
</div>

<!-- ══ BACK BUTTON ══ -->
<button class="back-btn" id="backBtn" onclick="closePanel()">
  <svg viewBox="0 0 24 24"><polyline points="15 18 9 12 15 6"></polyline></svg>
  Back
</button>

<!-- ══ CLUSTER NAV ══ -->
<div class="cluster-nav" id="clusterNav"></div>

<!-- ══ NAVIGATION SIDEBAR ══ -->
<nav class="deck-nav" id="deckNav">
  <div class="deck-nav-inner">
    <!-- Branding integrated into nav card -->
    <div class="brand-overlay" id="brandOverlay">
      <img src="https://www.stripes.co/dist/svg/logo-black.svg" alt="Stripes" class="brand-logo" onerror="this.outerHTML='<span style=font-weight:800;letter-spacing:.05em>///\\ STRIPES</span>'">
      <span class="x-mark">×</span>
      <span class="iso-logo" style="height:20px;opacity:.9">
        <svg class="iso-frame" viewBox="0 0 259 40" xmlns="http://www.w3.org/2000/svg"><path fill="#1E1E1E" d="M258.8,5.6v28.9c0,3.1-2.5,5.6-5.6,5.6h-64.1c-2.2,0-4.1-1.3-5-3.1c-0.9,1.9-2.8,3.1-5,3.1H45.5c-2.2,0-4.1-1.3-5-3.1c-0.9,1.8-2.8,3.1-5,3.1h-30C2.5,40,0,37.5,0,34.4V5.6C0,2.5,2.5,0,5.6,0h30c2.2,0,4.1,1.3,5,3.1c0.9-1.8,2.8-3.1,5-3.1h133.6c2.2,0,4.1,1.3,5,3.1c0.9-1.9,2.8-3.1,5-3.1h64.1C256.3,0,258.8,2.5,258.8,5.6L258.8,5.6zM40,34.4V5.6c0-2.5-2-4.4-4.4-4.4h-30c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.4,2,4.4,4.4,4.4h30C38,38.9,39.9,36.9,40,34.4zM183.6,34.4V5.6c0-2.4-2-4.4-4.4-4.4H45.5c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.5,2,4.4,4.4,4.4h133.6C181.6,38.9,183.6,36.9,183.6,34.4zM257.7,5.6c0-2.4-2-4.4-4.4-4.4h-64.1c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.4,2,4.4,4.4,4.4h64.1c2.4,0,4.4-2,4.4-4.4V5.6z"/><path fill="#1E1E1E" transform="translate(9.065,1.4) scale(0.93)" d="M52.3,28.1h2.5V9.5h-2.5V28.1zM65.9,21.2c-0.3-0.2-0.6-0.3-1-0.4c-0.4-0.1-1.1-0.3-2.3-0.6c-1.3-0.3-1.6-0.4-1.9-0.5c-0.8-0.3-1.1-0.7-1.1-1.4c0-1.2,1-2,2.6-2c1.6,0,3,0.8,3.7,2.2l1.7-1.3c-0.8-1.7-2.9-2.8-5.2-2.8c-1.5,0-2.6,0.4-3.6,1.2c-0.9,0.8-1.4,1.7-1.4,2.9c0,1.2,0.4,2.1,1.5,2.7c0.3,0.2,0.6,0.4,1.1,0.5c0.4,0.1,1.1,0.3,2,0.5c0.8,0.2,1.3,0.3,1.6,0.4c0.2,0.1,0.5,0.1,0.6,0.2c0.9,0.3,1.3,0.8,1.3,1.6c0,1.3-1.2,2.1-3,2.1s-3.4-1-4.1-2.5l-1.8,1.3c1,2,3.3,3.2,6,3.2c1.5,0,2.7-0.4,3.8-1.2c1-0.8,1.5-1.8,1.5-3.1C67.6,22.8,67.1,21.9,65.9,21.2zM80,16.4c1.1,1.2,1.6,3,1.6,4.9s-0.6,3.7-1.6,4.9c-1.1,1.3-2.8,2.1-4.7,2.1c-1.9,0-3.5-0.8-4.7-2.1c-1.1-1.2-1.6-3-1.6-4.9s0.6-3.7,1.6-4.9c1.1-1.3,2.8-2.1,4.7-2.1C77.2,14.3,78.9,15.1,80,16.4zM79.3,21.4c0-3.1-1.6-5.1-3.9-5.1c-2.4,0-3.9,2-3.9,5.1s1.6,5.1,3.9,5.1C77.8,26.4,79.3,24.5,79.3,21.4zM98.2,14.3c-1.8,0-3.4,0.9-4.3,2.3c-0.7-1.5-2-2.3-3.8-2.3c-1.7,0-3.1,0.8-3.9,2.1v-1.8h-2.3v13.5h2.3V20c0-1,0.3-1.8,0.9-2.5c0.6-0.6,1.5-1.1,2.3-1.1c1.7,0,2.7,1.2,2.7,3.3v8.3h2.3V20c0-1,0.3-1.8,0.9-2.5c0.6-0.6,1.5-1.1,2.3-1.1c1.7,0,2.7,1.2,2.7,3.3v8.3h2.3v-8.9C102.6,16.3,100.9,14.3,98.2,14.3zM115.6,16.4c1.1,1.2,1.6,3,1.6,4.9s-0.6,3.7-1.6,4.9c-1.1,1.3-2.8,2.1-4.7,2.1s-3.5-0.8-4.7-2.1c-1.1-1.2-1.6-3-1.6-4.9s0.6-3.7,1.6-4.9c1.1-1.3,2.8-2.1,4.7-2.1S114.5,15.1,115.6,16.4zM114.9,21.4c0-3.1-1.6-5.1-3.9-5.1c-2.4,0-3.9,2-3.9,5.1s1.6,5.1,3.9,5.1C113.4,26.4,114.9,24.5,114.9,21.4zM121.8,16.3v-1.7h-2.3v13.5h2.3v-7.4c0-1.2-0.1-2.5,0.6-3.2c0.5-0.5,0.9-0.6,1.9-0.6c0.4,0,2.1,0,2.1,0v-2.3h-2.2C123.7,14.6,122.4,14.8,121.8,16.3zM139.1,16.5c0.9,1.3,1.5,3,1.5,4.9s-0.5,3.6-1.5,4.9c-1.1,1.4-2.6,2.2-4.4,2.2c-1.8,0-3.4-0.8-4.2-2.3v6.6h-2.3V14.6h2.3v2c0.9-1.4,2.4-2.2,4.2-2.2C136.5,14.3,138.1,15.1,139.1,16.5zM138.2,21.4c0-3-1.5-5-4-5c-2.3,0-3.8,1.7-3.8,4.5v1c0,2.8,1.6,4.5,3.8,4.5C136.7,26.4,138.2,24.4,138.2,21.4zM149.1,14.3c-1.7,0-3.1,0.8-4,2.1V9.5h-2.3v18.6h2.3v-8.1c0-1,0.3-1.9,1-2.5c0.7-0.7,1.5-1,2.4-1c1.8,0,2.8,1.2,2.8,3.3v8.3h2.3v-8.9C153.6,16.2,151.9,14.3,149.1,14.3zM156.4,28.1h2.3V14.6h-2.3V28.1zM156.1,12.6h2.9v-3h-2.9V12.6zM167.4,26.4c-2.5,0-4.1-2-4.1-5s1.6-5,4.1-5c1.7,0,3,1,3.4,2.9l2-1c-0.7-2.4-2.7-3.9-5.4-3.9c-1.9,0-3.6,0.7-4.7,2.1c-1.1,1.3-1.7,3-1.7,5s0.6,3.7,1.7,5c1.1,1.3,2.8,2.1,4.7,2.1c2.7,0,4.7-1.6,5.4-4l-2.1-1C170.3,25.3,169.1,26.4,167.4,26.4zM198.6,9.5h-2.5v18.6h11.8V26h-9.3V9.5zM220.2,26.1h1.2v2h-2.8c-0.7,0-1.2-0.4-1.2-1.5c-0.9,1.1-2.6,1.8-4.4,1.8c-1.3,0-2.4-0.4-3.2-1.1c-0.8-0.7-1.2-1.7-1.2-2.8c0-2.3,1.5-3.7,5.1-4.4l3.3-0.7v-0.6c0-1.6-0.9-2.4-2.7-2.4c-1.7,0-2.7,0.8-3.1,2.3l-2.2-0.6c0.7-2.3,2.7-3.8,5.4-3.8c3.1,0,4.9,1.6,4.9,4.4v6.6C219.3,26,219.2,26.1,220.2,26.1zM217,21.2l-2.6,0.6c-2.6,0.5-3.5,1.3-3.5,2.6c0,1.3,0.9,2.1,2.4,2.1c1,0,1.9-0.3,2.6-0.8c0.7-0.6,1.1-1.3,1.1-2.1V21.2zM233.7,16.5c0.9,1.3,1.5,3,1.5,4.9s-0.5,3.6-1.5,4.9c-1.1,1.4-2.6,2.2-4.4,2.2s-3.4-0.8-4.2-2.3v2h-2.3V9.5h2.3v7c0.9-1.4,2.4-2.2,4.2-2.2C231.1,14.3,232.7,15.1,233.7,16.5zM232.8,21.4c0-3-1.5-5-4-5c-2.3,0-3.8,1.7-3.8,4.5v1c0,2.8,1.6,4.5,3.8,4.5C231.3,26.4,232.8,24.4,232.8,21.4zM245.5,21.2c-0.3-0.2-0.6-0.3-1-0.4c-0.4-0.1-1.1-0.3-2.3-0.6c-1.3-0.3-1.6-0.4-1.9-0.5c-0.8-0.3-1.1-0.7-1.1-1.4c0-1.2,1-2,2.6-2c1.6,0,3,0.8,3.7,2.2l1.7-1.3c-0.8-1.7-2.9-2.8-5.2-2.8c-1.4,0-2.6,0.4-3.6,1.2c-0.9,0.8-1.4,1.7-1.4,2.9c0,1.2,0.4,2.1,1.4,2.7c0.3,0.2,0.6,0.4,1.1,0.5c0.4,0.1,1.1,0.3,2,0.5c0.8,0.2,1.3,0.3,1.6,0.4c0.2,0.1,0.5,0.1,0.6,0.2c0.9,0.3,1.3,0.8,1.3,1.6c0,1.3-1.2,2.1-3,2.1c-1.8,0-3.4-1-4.1-2.5l-1.8,1.3c1,2,3.3,3.2,6,3.2c1.5,0,2.7-0.4,3.8-1.2c1-0.8,1.5-1.8,1.5-3.1C247.1,22.8,246.6,21.9,245.5,21.2z"/></svg>
        <span class="iso-lottie" data-iso-lottie style="width:15.4%;height:100%;border-radius:2px"></span>
      </span>
    </div>
    <div class="nav-section expanded">
      <div class="nav-section-title" onclick="toggleNavSection(this)">
        <span class="nav-section-icon" style="background:#635BFF"></span>
        Introduction
        <span class="nav-chevron">&#9662;</span>
      </div>
      <div class="nav-section-items">
        <button class="nav-item" data-target="hero" style="--nav-accent:#635BFF">Cover</button>
        <button class="nav-item" data-target="investments" style="--nav-accent:#80E9FF">Recent Investments</button>
      </div>
    </div>
    <div class="nav-section">
      <div class="nav-section-title" onclick="toggleNavSection(this)">
        <span class="nav-section-icon" style="background:#E85D75"></span>
        Industry Landscape
        <span class="nav-chevron">&#9662;</span>
      </div>
      <div class="nav-section-items">
        <button class="nav-item" data-target="rdcrisis" style="--nav-accent:#E85D75">R&D Productivity Crisis</button>
        <button class="nav-item" data-target="trialheadwinds" style="--nav-accent:#FF7A00">Clinical Trial Headwinds</button>
        <button class="nav-item" data-target="aivalue" style="--nav-accent:#635BFF">AI Across Pharma</button>
        <button class="nav-item" data-target="rdparadigms" style="--nav-accent:#80E9FF">R&D Paradigms</button>
      </div>
    </div>
    <div class="nav-section">
      <div class="nav-section-title" onclick="toggleNavSection(this)">
        <span class="nav-section-icon" style="background:#FF4D6D"></span>
        Our Perspective
        <span class="nav-chevron">&#9662;</span>
      </div>
      <div class="nav-section-items">
        <button class="nav-item" data-target="inflection" style="--nav-accent:#FF4D6D">Pharma Inflection</button>
        <button class="nav-item" data-target="diligence" style="--nav-accent:#24D164">Market Diligence</button>
        <button class="nav-item" data-target="thesis" style="--nav-accent:#635BFF">Investment Thesis</button>
        <button class="nav-item" data-target="uvp" style="--nav-accent:#80E9FF">Unique Value Prop</button>
        <button class="nav-item" data-target="validation" style="--nav-accent:#E21937">Partner Case Study</button>
        <button class="nav-item" data-target="competitive" style="--nav-accent:#FF5CAA">Competitive Landscape</button>
        <button class="nav-item" data-target="growth" style="--nav-accent:#24D164">Growth Vectors</button>
        <button class="nav-item" data-target="risks" style="--nav-accent:#FF7A00">Risks & Mitigants</button>
      </div>
    </div>
    <div class="nav-section">
      <div class="nav-section-title" onclick="toggleNavSection(this)">
        <span class="nav-section-icon" style="background:#635BFF"></span>
        Our Team
        <span class="nav-chevron">&#9662;</span>
      </div>
      <div class="nav-section-items">
        <button class="nav-item" data-target="team" style="--nav-accent:#635BFF">Stripes Overview</button>
        <button class="nav-item" data-target="scaleteam" style="--nav-accent:#24D164">Scale Team</button>
        <button class="nav-item" data-target="healthcare" style="--nav-accent:#FF6B9D">Healthcare Expertise</button>
        <button class="nav-item" data-target="ops" style="--nav-accent:#80E9FF">Our Network</button>
        <button class="nav-item" data-target="end" style="--nav-accent:#635BFF">Thank You</button>
      </div>
    </div>
  </div>
</nav>

<!-- ══ CONTENT PANELS ══ -->
<div id="content-panels">

  <!-- HERO -->
  <div class="content-panel" data-node="hero">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#635BFF,#80E9FF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Introduction</span><span class="bc-sep">›</span><span style="color:var(--accent)">Cover</span></div>
      <div class="hero-content">
        <div class="hero-eyebrow">
          <img src="https://www.stripes.co/dist/svg/logo-black.svg" alt="Stripes" class="brand-logo-lg" onerror="this.outerHTML='<span style=font-weight:800;letter-spacing:.05em>///\\ STRIPES</span>'">
          <span class="x-mark">×</span>
          <span class="iso-logo" style="height:28px">
            <svg class="iso-frame" viewBox="0 0 259 40" xmlns="http://www.w3.org/2000/svg"><path fill="#1E1E1E" d="M258.8,5.6v28.9c0,3.1-2.5,5.6-5.6,5.6h-64.1c-2.2,0-4.1-1.3-5-3.1c-0.9,1.9-2.8,3.1-5,3.1H45.5c-2.2,0-4.1-1.3-5-3.1c-0.9,1.8-2.8,3.1-5,3.1h-30C2.5,40,0,37.5,0,34.4V5.6C0,2.5,2.5,0,5.6,0h30c2.2,0,4.1,1.3,5,3.1c0.9-1.8,2.8-3.1,5-3.1h133.6c2.2,0,4.1,1.3,5,3.1c0.9-1.9,2.8-3.1,5-3.1h64.1C256.3,0,258.8,2.5,258.8,5.6L258.8,5.6zM40,34.4V5.6c0-2.5-2-4.4-4.4-4.4h-30c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.4,2,4.4,4.4,4.4h30C38,38.9,39.9,36.9,40,34.4zM183.6,34.4V5.6c0-2.4-2-4.4-4.4-4.4H45.5c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.5,2,4.4,4.4,4.4h133.6C181.6,38.9,183.6,36.9,183.6,34.4zM257.7,5.6c0-2.4-2-4.4-4.4-4.4h-64.1c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.4,2,4.4,4.4,4.4h64.1c2.4,0,4.4-2,4.4-4.4V5.6z"/><path fill="#1E1E1E" transform="translate(9.065,1.4) scale(0.93)" d="M52.3,28.1h2.5V9.5h-2.5V28.1zM65.9,21.2c-0.3-0.2-0.6-0.3-1-0.4c-0.4-0.1-1.1-0.3-2.3-0.6c-1.3-0.3-1.6-0.4-1.9-0.5c-0.8-0.3-1.1-0.7-1.1-1.4c0-1.2,1-2,2.6-2c1.6,0,3,0.8,3.7,2.2l1.7-1.3c-0.8-1.7-2.9-2.8-5.2-2.8c-1.5,0-2.6,0.4-3.6,1.2c-0.9,0.8-1.4,1.7-1.4,2.9c0,1.2,0.4,2.1,1.5,2.7c0.3,0.2,0.6,0.4,1.1,0.5c0.4,0.1,1.1,0.3,2,0.5c0.8,0.2,1.3,0.3,1.6,0.4c0.2,0.1,0.5,0.1,0.6,0.2c0.9,0.3,1.3,0.8,1.3,1.6c0,1.3-1.2,2.1-3,2.1s-3.4-1-4.1-2.5l-1.8,1.3c1,2,3.3,3.2,6,3.2c1.5,0,2.7-0.4,3.8-1.2c1-0.8,1.5-1.8,1.5-3.1C67.6,22.8,67.1,21.9,65.9,21.2zM80,16.4c1.1,1.2,1.6,3,1.6,4.9s-0.6,3.7-1.6,4.9c-1.1,1.3-2.8,2.1-4.7,2.1c-1.9,0-3.5-0.8-4.7-2.1c-1.1-1.2-1.6-3-1.6-4.9s0.6-3.7,1.6-4.9c1.1-1.3,2.8-2.1,4.7-2.1C77.2,14.3,78.9,15.1,80,16.4zM79.3,21.4c0-3.1-1.6-5.1-3.9-5.1c-2.4,0-3.9,2-3.9,5.1s1.6,5.1,3.9,5.1C77.8,26.4,79.3,24.5,79.3,21.4zM98.2,14.3c-1.8,0-3.4,0.9-4.3,2.3c-0.7-1.5-2-2.3-3.8-2.3c-1.7,0-3.1,0.8-3.9,2.1v-1.8h-2.3v13.5h2.3V20c0-1,0.3-1.8,0.9-2.5c0.6-0.6,1.5-1.1,2.3-1.1c1.7,0,2.7,1.2,2.7,3.3v8.3h2.3V20c0-1,0.3-1.8,0.9-2.5c0.6-0.6,1.5-1.1,2.3-1.1c1.7,0,2.7,1.2,2.7,3.3v8.3h2.3v-8.9C102.6,16.3,100.9,14.3,98.2,14.3zM115.6,16.4c1.1,1.2,1.6,3,1.6,4.9s-0.6,3.7-1.6,4.9c-1.1,1.3-2.8,2.1-4.7,2.1s-3.5-0.8-4.7-2.1c-1.1-1.2-1.6-3-1.6-4.9s0.6-3.7,1.6-4.9c1.1-1.3,2.8-2.1,4.7-2.1S114.5,15.1,115.6,16.4zM114.9,21.4c0-3.1-1.6-5.1-3.9-5.1c-2.4,0-3.9,2-3.9,5.1s1.6,5.1,3.9,5.1C113.4,26.4,114.9,24.5,114.9,21.4zM121.8,16.3v-1.7h-2.3v13.5h2.3v-7.4c0-1.2-0.1-2.5,0.6-3.2c0.5-0.5,0.9-0.6,1.9-0.6c0.4,0,2.1,0,2.1,0v-2.3h-2.2C123.7,14.6,122.4,14.8,121.8,16.3zM139.1,16.5c0.9,1.3,1.5,3,1.5,4.9s-0.5,3.6-1.5,4.9c-1.1,1.4-2.6,2.2-4.4,2.2c-1.8,0-3.4-0.8-4.2-2.3v6.6h-2.3V14.6h2.3v2c0.9-1.4,2.4-2.2,4.2-2.2C136.5,14.3,138.1,15.1,139.1,16.5zM138.2,21.4c0-3-1.5-5-4-5c-2.3,0-3.8,1.7-3.8,4.5v1c0,2.8,1.6,4.5,3.8,4.5C136.7,26.4,138.2,24.4,138.2,21.4zM149.1,14.3c-1.7,0-3.1,0.8-4,2.1V9.5h-2.3v18.6h2.3v-8.1c0-1,0.3-1.9,1-2.5c0.7-0.7,1.5-1,2.4-1c1.8,0,2.8,1.2,2.8,3.3v8.3h2.3v-8.9C153.6,16.2,151.9,14.3,149.1,14.3zM156.4,28.1h2.3V14.6h-2.3V28.1zM156.1,12.6h2.9v-3h-2.9V12.6zM167.4,26.4c-2.5,0-4.1-2-4.1-5s1.6-5,4.1-5c1.7,0,3,1,3.4,2.9l2-1c-0.7-2.4-2.7-3.9-5.4-3.9c-1.9,0-3.6,0.7-4.7,2.1c-1.1,1.3-1.7,3-1.7,5s0.6,3.7,1.7,5c1.1,1.3,2.8,2.1,4.7,2.1c2.7,0,4.7-1.6,5.4-4l-2.1-1C170.3,25.3,169.1,26.4,167.4,26.4zM198.6,9.5h-2.5v18.6h11.8V26h-9.3V9.5zM220.2,26.1h1.2v2h-2.8c-0.7,0-1.2-0.4-1.2-1.5c-0.9,1.1-2.6,1.8-4.4,1.8c-1.3,0-2.4-0.4-3.2-1.1c-0.8-0.7-1.2-1.7-1.2-2.8c0-2.3,1.5-3.7,5.1-4.4l3.3-0.7v-0.6c0-1.6-0.9-2.4-2.7-2.4c-1.7,0-2.7,0.8-3.1,2.3l-2.2-0.6c0.7-2.3,2.7-3.8,5.4-3.8c3.1,0,4.9,1.6,4.9,4.4v6.6C219.3,26,219.2,26.1,220.2,26.1zM217,21.2l-2.6,0.6c-2.6,0.5-3.5,1.3-3.5,2.6c0,1.3,0.9,2.1,2.4,2.1c1,0,1.9-0.3,2.6-0.8c0.7-0.6,1.1-1.3,1.1-2.1V21.2zM233.7,16.5c0.9,1.3,1.5,3,1.5,4.9s-0.5,3.6-1.5,4.9c-1.1,1.4-2.6,2.2-4.4,2.2s-3.4-0.8-4.2-2.3v2h-2.3V9.5h2.3v7c0.9-1.4,2.4-2.2,4.2-2.2C231.1,14.3,232.7,15.1,233.7,16.5zM232.8,21.4c0-3-1.5-5-4-5c-2.3,0-3.8,1.7-3.8,4.5v1c0,2.8,1.6,4.5,3.8,4.5C231.3,26.4,232.8,24.4,232.8,21.4zM245.5,21.2c-0.3-0.2-0.6-0.3-1-0.4c-0.4-0.1-1.1-0.3-2.3-0.6c-1.3-0.3-1.6-0.4-1.9-0.5c-0.8-0.3-1.1-0.7-1.1-1.4c0-1.2,1-2,2.6-2c1.6,0,3,0.8,3.7,2.2l1.7-1.3c-0.8-1.7-2.9-2.8-5.2-2.8c-1.4,0-2.6,0.4-3.6,1.2c-0.9,0.8-1.4,1.7-1.4,2.9c0,1.2,0.4,2.1,1.4,2.7c0.3,0.2,0.6,0.4,1.1,0.5c0.4,0.1,1.1,0.3,2,0.5c0.8,0.2,1.3,0.3,1.6,0.4c0.2,0.1,0.5,0.1,0.6,0.2c0.9,0.3,1.3,0.8,1.3,1.6c0,1.3-1.2,2.1-3,2.1c-1.8,0-3.4-1-4.1-2.5l-1.8,1.3c1,2,3.3,3.2,6,3.2c1.5,0,2.7-0.4,3.8-1.2c1-0.8,1.5-1.8,1.5-3.1C247.1,22.8,246.6,21.9,245.5,21.2z"/></svg>
            <span class="iso-lottie" data-iso-lottie style="width:15.4%;height:100%;border-radius:3px"></span>
          </span>
        </div>
        <h1>Reimagining<br><span class="gradient-text">Drug Discovery</span><br>with AI</h1>
        <p>Stripes is an NYC-based growth equity firm led by entrepreneurs and operators. We invest in and actively support best-in-class, category-defining companies. We believe Isomorphic Labs will revolutionize drug discovery.</p>
        <div class="hero-meta">
          <div class="hero-meta-item"><span class="val" data-count="8" data-prefix="$" data-suffix="B">$0B</span><span class="lbl">AUM</span></div>
          <div class="hero-meta-item"><span class="val">Fund VII</span><span class="lbl">Current Fund</span></div>
          <div class="hero-meta-item"><span class="val">NYC</span><span class="lbl">Headquartered</span></div>
        </div>
        <div class="logo-row" style="margin-top:40px">
          <div class="lr-item"><div class="lr-icon no-pad" style="background:#6161FF"><img src="https://www.google.com/s2/favicons?domain=monday.com&sz=128" alt="monday.com"></div><div class="lr-name">monday.com</div></div>
          <div class="lr-item"><div class="lr-icon no-pad" style="background:#1DBE72"><img src="https://www.google.com/s2/favicons?domain=ramp.com&sz=128" alt="Ramp"></div><div class="lr-name">Ramp</div></div>
          <div class="lr-item"><div class="lr-icon no-pad" style="background:#000;border:1px solid #333"><img src="https://www.google.com/s2/favicons?domain=a24films.com&sz=128" alt="A24"></div><div class="lr-name">A24</div></div>
          <div class="lr-item"><div class="lr-icon no-pad" style="background:#2C56DD"><img src="https://www.google.com/s2/favicons?domain=dataiku.com&sz=128" alt="Dataiku"></div><div class="lr-name">Dataiku</div></div>
          <div class="lr-item"><div class="lr-icon no-pad" style="background:#000;border:1px solid #333"><img src="https://www.google.com/s2/favicons?domain=on-running.com&sz=128" alt="On Running"></div><div class="lr-name">On Running</div></div>
          <div class="lr-item"><div class="lr-icon no-pad" style="background:#4C4AE6"><img src="https://www.google.com/s2/favicons?domain=snyk.io&sz=128" alt="Snyk"></div><div class="lr-name">Snyk</div></div>
        </div>
      </div>
    </div>
  </div>

  <!-- RECENT INVESTMENTS -->
  <div class="content-panel" data-node="investments">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#80E9FF,#635BFF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Introduction</span><span class="bc-sep">›</span><span style="color:#80E9FF">Recent Investments</span></div>
      <div class="label">Category-Defining Investments</div>
      <h2 class="sec-title">Our recent investments</h2>
      <p class="sec-sub">Stripes partners with founders building n-of-1, category-defining companies with enormous opportunity. We look for <strong style="color:var(--text)">amazing products</strong> with <strong style="color:var(--text)">amazing market opportunities.</strong></p>
      <div class="data-table-wrap">
        <table class="data-table">
          <thead><tr><th>Company</th><th>Overview</th><th>Round</th></tr></thead>
          <tbody>
            <tr><td><div style="display:flex;align-items:center;gap:8px"><div class="lr-icon no-pad" style="background:#FF3621;width:28px;height:28px;border-radius:6px"><img src="https://www.google.com/s2/favicons?domain=databricks.com&sz=128" alt="DB"></div><span class="em">Databricks</span></div></td><td>Leading data infrastructure platform</td><td class="hl">$10B, Dec 2024</td></tr>
            <tr><td><div style="display:flex;align-items:center;gap:8px"><div class="lr-icon no-pad" style="background:#1DBE72;width:28px;height:28px;border-radius:6px"><img src="https://www.google.com/s2/favicons?domain=ramp.com&sz=128" alt="Ramp"></div><span class="em">Ramp</span></div></td><td>Finance automation platform</td><td class="hl">$150M, Dec 2024</td></tr>
            <tr><td><div style="display:flex;align-items:center;gap:8px"><div class="lr-icon no-pad" style="background:#0047AB;width:28px;height:28px;border-radius:6px"><img src="https://www.google.com/s2/favicons?domain=appliedintuition.com&sz=128" alt="AI"></div><span class="em">Applied Intuition</span></div></td><td>Autonomous mobility solutions</td><td class="hl">Undisclosed</td></tr>
            <tr><td><div style="display:flex;align-items:center;gap:8px"><div class="lr-icon no-pad" style="background:#1E88E5;width:28px;height:28px;border-radius:6px"><img src="https://www.google.com/s2/favicons?domain=flocksafety.com&sz=128" alt="FS"></div><span class="em">Flock Safety</span></div></td><td>AI-powered public safety</td><td class="hl">$275M, Mar 2025</td></tr>
            <tr><td><div style="display:flex;align-items:center;gap:8px"><div class="lr-icon no-pad" style="background:#C45A3C;width:28px;height:28px;border-radius:6px"><img src="https://www.google.com/s2/favicons?domain=vuoriclothing.com&sz=128" alt="V"></div><span class="em">Vuori</span></div></td><td>Premium athleisure brand</td><td class="hl">$825M, Nov 2024</td></tr>
          </tbody>
        </table>
      </div>
      <div class="callout">We believe Isomorphic Labs will be a highly sought-after business for public market investors — like On Running (NYSE: ONON, $19.5B) and Monday.com (NASDAQ: MNDY, $14.9B).</div>
    </div>
  </div>

  <!-- R&D PRODUCTIVITY CRISIS -->
  <div class="content-panel" data-node="rdcrisis">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#E85D75,#FF7A00)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Industry Landscape</span><span class="bc-sep">›</span><span style="color:#E85D75">R&D Productivity Crisis</span></div>
      <div class="label">Industry Landscape</div>
      <h2 class="sec-title">R&D is getting more expensive<br>without <span class="gradient-text">getting faster</span></h2>
      <p class="sec-sub">Convergence of challenges require new approaches to R&D. Structural pressures across pharma are creating a generational opening for AI-native drug discovery.</p>
      <div class="data-table-wrap" style="margin-top:32px">
        <table class="data-table">
          <thead><tr><th>Metric</th><th>Then</th><th>Now</th><th>Trend</th></tr></thead>
          <tbody>
            <tr><td class="em">Avg. annual R&D expenditure (top 15)</td><td>$5.3B (2011-15)</td><td><span class="hl">$6.0B</span> (2016-20)</td><td style="color:var(--red)">&#9650; Rising</td></tr>
            <tr><td class="em">Avg. years to complete Phase 2 & 3</td><td>6.5 years</td><td><span class="hl">7.1 years</span></td><td style="color:var(--red)">&#9650; Worsening</td></tr>
          </tbody>
        </table>
      </div>
      <h3 style="font-size:20px;margin:40px 0 20px;font-family:var(--font-g);font-weight:700">Compounding Challenges &amp; Delays</h3>
      <div class="data-table-wrap">
        <table class="data-table">
          <thead><tr><th>Increasing Pressure</th><th>Challenging Backdrop</th><th>Resulting Impact</th></tr></thead>
          <tbody>
            <tr><td><span class="hl">50%</span> decrease in years of MOA exclusivity (8 yrs in 2000-04 vs. 4 yrs in 2016+)</td><td><span class="hl">53%</span> of sites indicate insufficient bandwidth to run trials</td><td><span class="hl">22%</span> of trials have delays >40%</td></tr>
            <tr><td><span class="hl">40%</span> increase in patient trial slots in oncology (2016-21)</td><td><span class="hl">56%</span> increase in trial complexity vs. 3 years ago</td><td><span class="hl">80%</span> of sponsors not meeting DEI goals</td></tr>
          </tbody>
        </table>
      </div>
      <div class="callout" style="margin-top:32px;border-left:3px solid #E85D75"><strong>Isomorphic Labs positioning:</strong> AI-driven drug discovery can compress timelines, reduce trial complexity, and improve hit rates at the earliest stages — addressing the root causes of R&D productivity decline before costs compound through clinical development.</div>
      <p class="sec-sub" style="margin-top:24px;font-size:11px;color:var(--text3)">Source: Schumacher "Analysis of pharma R&D productivity" (Oct 2023); Bain "Clinical Trials at a Crossroads" (Jan 2023); Bain "Benchmarking and TSR" (Oct 2023)</p>
    </div>
  </div>

  <!-- CLINICAL TRIAL HEADWINDS -->
  <div class="content-panel" data-node="trialheadwinds">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#FF7A00,#C8A95A)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Industry Landscape</span><span class="bc-sep">›</span><span style="color:#FF7A00">Clinical Trial Headwinds</span></div>
      <div class="label">Industry Landscape</div>
      <h2 class="sec-title">Big pharma pulling back on trials<br><span class="gradient-text">smaller players filling the gap</span></h2>
      <p class="sec-sub">Top pharma companies are rationalizing trial portfolios — while smaller, more nimble companies (including AI-native biotechs) are driving the majority of new clinical activity.</p>
      <div class="data-table-wrap" style="margin-top:32px">
        <table class="data-table">
          <thead><tr><th>Year</th><th>Total Starts</th><th>"Others" Share</th><th>Growth</th></tr></thead>
          <tbody>
            <tr><td class="em">2015</td><td>3,951</td><td>53%</td><td rowspan="2" style="vertical-align:middle;color:var(--green)">+6% p.a.</td></tr>
            <tr><td class="em">2020</td><td>5,213</td><td>69%</td></tr>
            <tr><td class="em">2021</td><td><span class="hl">6,368</span> (peak)</td><td>72%</td><td style="color:var(--green)">+7% p.a.</td></tr>
            <tr><td class="em">2024</td><td>5,614</td><td><span class="hl">75%</span></td><td style="color:var(--red)">-3% p.a.</td></tr>
          </tbody>
        </table>
      </div>
      <div class="stat-grid" style="margin-top:32px">
        <div class="stat-card" style="--s-color:var(--red)"><div class="stat-val" data-count="4" data-prefix="-" data-suffix="%">0%</div><div class="stat-label">Top 10 Pharma CAGR (2022-24)</div><div class="stat-desc">Largest companies leading the decline, rationalizing portfolios</div><div class="mini-bar"><div class="mini-bar-fill" data-width="40%" style="background:var(--red)"></div></div></div>
        <div class="stat-card" style="--s-color:var(--orange)"><div class="stat-val" data-count="75" data-suffix="%">0%</div><div class="stat-label">"Others" Share of Trial Starts</div><div class="stat-desc">Up from 53% in 2015 — smaller companies driving clinical activity</div><div class="mini-bar"><div class="mini-bar-fill" data-width="75%" style="background:var(--orange)"></div></div></div>
        <div class="stat-card" style="--s-color:var(--accent)"><div class="stat-val" data-count="86" data-suffix="%">0%</div><div class="stat-label">Facing Cost Scrutiny</div><div class="stat-desc">Budget pressure pushing pharma to seek external innovation partners</div><div class="mini-bar"><div class="mini-bar-fill" data-width="86%" style="background:var(--accent)"></div></div></div>
      </div>
      <div class="callout" style="margin-top:32px;border-left:3px solid #FF7A00"><strong>Why this matters for Isomorphic:</strong> As big pharma consolidates trial activity and prioritizes capital efficiency, demand for AI platforms that de-risk early discovery and compress preclinical timelines will only accelerate. Isomorphic's partnerships with Lilly and Novartis position it as a critical infrastructure layer for this new model.</div>
      <p class="sec-sub" style="margin-top:24px;font-size:11px;color:var(--text3)">Source: Citeline Trialtrove as of July 2025; PharmaCo rankings by reported 2024 revenue</p>
    </div>
  </div>

  <!-- AI ACROSS PHARMA VALUE CHAIN -->
  <div class="content-panel" data-node="aivalue">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#635BFF,#24D164)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Industry Landscape</span><span class="bc-sep">›</span><span style="color:var(--accent)">AI Across Pharma</span></div>
      <div class="label">Industry Landscape</div>
      <h2 class="sec-title">AI adoption is scaling rapidly<br><span class="gradient-text">>50% of pharma have at least a POC</span></h2>
      <p class="sec-sub">The industry has moved past experimentation — the question is no longer "if" but "how fast."</p>
      <div class="data-table-wrap" style="margin-top:32px">
        <table class="data-table">
          <thead><tr><th>Stage</th><th>Company</th><th>Use Case</th><th>Detail</th></tr></thead>
          <tbody>
            <tr><td><span style="color:var(--accent);font-weight:600">Discovery</span></td><td class="em">Moderna + IBM</td><td>mRNA Candidate ID</td><td>Using GenAI to rapidly identify new mRNA vaccine candidates</td></tr>
            <tr><td><span style="color:var(--accent);font-weight:600">Discovery</span></td><td class="em">AstraZeneca</td><td>ML Pattern Recognition</td><td>Partnering with academia to spot patterns between healthy, diseased, and drug-treated tissue</td></tr>
            <tr><td><span style="color:var(--green);font-weight:600">Development</span></td><td class="em">Sanofi</td><td>Clinical Trial Optimization</td><td>Plai app identifies promising trial locations and participant information</td></tr>
            <tr><td><span style="color:var(--green);font-weight:600">Development</span></td><td class="em">Eli Lilly + Yseop</td><td>Study Report Automation</td><td>Automating patient narratives and clinical study reports</td></tr>
            <tr><td><span style="color:var(--green);font-weight:600">Development</span></td><td class="em">Pfizer + Concreto</td><td>Regulatory Filing</td><td>Accelerating outcome studies and regulatory submissions</td></tr>
            <tr><td><span style="color:var(--orange);font-weight:600">Supply</span></td><td class="em">Eli Lilly</td><td>Robotic Process AI</td><td>AI solutions to automate robotic manufacturing and identify inefficiencies</td></tr>
            <tr><td><span style="color:var(--pink);font-weight:600">Launch</span></td><td class="em">GSK + Tempus</td><td>Personalized Treatment</td><td>AI-enabled platform for personalized treatment; improving trial design</td></tr>
            <tr><td><span style="color:var(--pink);font-weight:600">Launch</span></td><td class="em">Novartis + Aktana</td><td>HCP Engagement</td><td>Better segmenting, engaging, and following up with healthcare providers</td></tr>
          </tbody>
        </table>
      </div>
      <div class="callout" style="margin-top:32px;border-left:3px solid var(--accent)"><strong>Discovery remains the highest-value, hardest-to-crack frontier,</strong> and Isomorphic Labs' AlphaFold-derived models give it a structural advantage in the most impactful segment of the value chain.</div>
      <p class="sec-sub" style="margin-top:24px;font-size:11px;color:var(--text3)">Source: Bain GenAI in Pharma Survey (N=100), Sept 2023; Company websites and earnings calls</p>
    </div>
  </div>

  <!-- EMERGING R&D PARADIGMS -->
  <div class="content-panel" data-node="rdparadigms">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#80E9FF,#635BFF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Industry Landscape</span><span class="bc-sep">›</span><span style="color:var(--accent2)">R&D Paradigms</span></div>
      <div class="label">Industry Landscape</div>
      <h2 class="sec-title">Three macro shifts are reshaping<br><span class="gradient-text">how pharma discovers drugs</span></h2>
      <p class="sec-sub">From new modalities to decentralized trials to ecosystem partnerships — the R&D landscape is transforming.</p>
      <div style="margin-top:36px">
        <div style="margin-bottom:36px">
          <h3 style="font-size:20px;font-family:var(--font-g);margin-bottom:16px"><span style="display:inline-block;width:28px;height:28px;border-radius:50%;background:var(--accent);color:#fff;text-align:center;line-height:28px;font-family:var(--font-b);font-size:13px;font-weight:600;margin-right:10px;vertical-align:middle">1</span>Rapid Expansion of Treatment Modalities</h3>
          <ul style="list-style:none;display:flex;flex-direction:column;gap:10px;padding-left:38px">
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--accent)">&#8226;</span>Massive expansion from frontier (CRISPR, microbiome) to emerging (gene/cell therapies, bispecific antibodies) to mature (mAbs, small molecule)</li>
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--accent)">&#8226;</span>Significantly more complex choice set for R&D orgs to prioritize across TAs, modalities, and MOAs</li>
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--accent)">&#8226;</span>Ramifications cascade across the entire value chain: manufacturing, distribution, and customer engagement</li>
          </ul>
        </div>
        <div style="margin-bottom:36px">
          <h3 style="font-size:20px;font-family:var(--font-g);margin-bottom:16px"><span style="display:inline-block;width:28px;height:28px;border-radius:50%;background:var(--green);color:#fff;text-align:center;line-height:28px;font-family:var(--font-b);font-size:13px;font-weight:600;margin-right:10px;vertical-align:middle">2</span>New Clinical Development Paradigms</h3>
          <ul style="list-style:none;display:flex;flex-direction:column;gap:10px;padding-left:38px">
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--green)">&#8226;</span>Disruption of traditional Phase I &#8594; II &#8594; III paradigm — adaptive trial designs, fast-tracking, post-market evidence</li>
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--green)">&#8226;</span>Growing adoption of decentralized / virtualized trial designs, accelerated by persistent site resourcing challenges</li>
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--green)">&#8226;</span>Increased blending of clinical and real-world data to reduce costs (e.g., digital twins)</li>
          </ul>
        </div>
        <div style="margin-bottom:36px">
          <h3 style="font-size:20px;font-family:var(--font-g);margin-bottom:16px"><span style="display:inline-block;width:28px;height:28px;border-radius:50%;background:var(--pink);color:#fff;text-align:center;line-height:28px;font-family:var(--font-b);font-size:13px;font-weight:600;margin-right:10px;vertical-align:middle">3</span>Diverse Ecosystem Engagement Models</h3>
          <ul style="list-style:none;display:flex;flex-direction:column;gap:10px;padding-left:38px">
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--pink)">&#8226;</span>Increasing growth and maturity in pharma-enabling ecosystem, seeded by recent venture funding boom</li>
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--pink)">&#8226;</span>Expansion of collaboration models — academia, startups, big tech, CRO/CDMO</li>
            <li style="position:relative;padding-left:16px;color:var(--text2);line-height:1.6"><span style="position:absolute;left:0;color:var(--pink)">&#8226;</span>Managing complex ecosystem partnerships has become a core competency</li>
          </ul>
        </div>
      </div>
      <div class="callout" style="border-left:3px solid var(--accent2)"><strong>Isomorphic sits at the intersection of all three shifts:</strong> AlphaFold 3 enables work across modalities (platform play); AI-designed molecules reduce clinical cost and time; partnerships with Lilly and Novartis represent the gold-standard AI-pharma collaboration model.</div>
      <p class="sec-sub" style="margin-top:24px;font-size:11px;color:var(--text3)">Source: Bain R&D Analysis; Industry participant interviews</p>
    </div>
  </div>

  <!-- PHARMA INFLECTION -->
  <div class="content-panel" data-node="inflection">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#FF4D6D,#FF7A00)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Perspective</span><span class="bc-sep">›</span><span style="color:#FF4D6D">Pharma Inflection</span></div>
      <div class="label">Market Thesis</div>
      <h2 class="sec-title">The pharma industry is at<br>an <span class="gradient-text">inflection point</span></h2>
      <p class="sec-sub">Pharma is under unprecedented pressure to do more with less — creating a "burning platform" for AI-enabled drug discovery.</p>
      <div class="stat-grid">
        <div class="stat-card" style="--s-color:var(--accent)"><div class="stat-val" data-count="351" data-prefix="$" data-suffix="B">$0B</div><div class="stat-label">Global Pharma R&D Spend</div><div class="stat-desc">Growth decelerating from ~5% to 2–3% "new normal"</div><div class="mini-bar"><div class="mini-bar-fill" data-width="85%" style="background:var(--accent)"></div></div></div>
        <div class="stat-card" style="--s-color:var(--red)"><div class="stat-val" data-count="86" data-suffix="%">0%</div><div class="stat-label">Cost Scrutiny</div><div class="stat-desc">Clinical dev leaders report increased cost scrutiny on programs</div><div class="mini-bar"><div class="mini-bar-fill" data-width="86%" style="background:var(--red)"></div></div></div>
        <div class="stat-card" style="--s-color:var(--orange)"><div class="stat-val" data-count="75" data-prefix="~" data-suffix="%">0%</div><div class="stat-label">Revenue at Risk</div><div class="stat-desc">Top 20 pharma revenue at risk from patent cliffs & IRA pricing</div><div class="mini-bar"><div class="mini-bar-fill" data-width="75%" style="background:var(--orange)"></div></div></div>
        <div class="stat-card" style="--s-color:var(--pink)"><div class="stat-val" data-count="7.1" data-suffix="yr" data-decimals="1">0yr</div><div class="stat-label">Phase 2/3 Timelines</div><div class="stat-desc">Extended from 6.5 years despite growing R&D spend</div><div class="mini-bar"><div class="mini-bar-fill" data-width="71%" style="background:var(--pink)"></div></div></div>
        <div class="stat-card" style="--s-color:var(--accent2)"><div class="stat-val" data-count="3" data-prefix="-" data-suffix="%" data-decimals="0">0%</div><div class="stat-label">Trial Starts p.a.</div><div class="stat-desc">Since 2022 — sponsors becoming more selective</div><div class="mini-bar"><div class="mini-bar-fill" data-width="30%" style="background:var(--accent2)"></div></div></div>
        <div class="stat-card" style="--s-color:var(--green)"><div class="stat-val" data-count="50" data-suffix="%">0%</div><div class="stat-label">MOA Window Shrunk</div><div class="stat-desc">From ~8 years to ~4 years — speed-to-market critical</div><div class="mini-bar"><div class="mini-bar-fill" data-width="50%" style="background:var(--green)"></div></div></div>
      </div>
      <h3 style="font-size:20px;margin:48px 0 20px;font-family:var(--font-g);font-weight:700">Pharma's Response: Embracing AI</h3>
      <div class="data-table-wrap">
        <table class="data-table">
          <thead><tr><th>Finding</th><th>Detail</th></tr></thead>
          <tbody>
            <tr><td class="em">Top 20 Pharma AI Adoption</td><td><span class="hl">50%</span> of Top 20 Pharma and <span class="hl">55%</span> of $1B–$10B companies prioritize tool adoption</td></tr>
            <tr><td class="em">AI POC Penetration</td><td>>50% have POC for AI in R&D; only <span class="hl">15%</span> in full rollout — massive whitespace</td></tr>
            <tr><td class="em">Vendor Scrutiny</td><td><span class="hl">41%</span> of sponsors being more cost-conscious with vendors</td></tr>
            <tr><td class="em">AI Governance</td><td>Pharma restricting AI to approved use cases — favors <strong style="color:var(--text)">secure, enterprise-grade platforms</strong> like Isomorphic</td></tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>

  <!-- MARKET DILIGENCE -->
  <div class="content-panel" data-node="diligence">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#24D164,#80E9FF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Perspective</span><span class="bc-sep">›</span><span style="color:#24D164">Market Diligence</span></div>
      <div class="label">Market Diligence</div>
      <h2 class="sec-title">What we heard from<br>customers & experts</h2>
      <p class="sec-sub">Stripes conducted expert calls with senior pharma and biotech leaders to validate Isomorphic's competitive position.</p>
      <div class="logo-row" style="margin-bottom:40px">
        <div class="lr-item"><div class="lr-icon no-pad" style="background:#E21937"><img src="https://www.google.com/s2/favicons?domain=lilly.com&sz=128" alt="Eli Lilly"></div><div class="lr-name">Eli Lilly</div></div>
        <div class="lr-item"><div class="lr-icon no-pad" style="background:#0460A9"><img src="https://www.google.com/s2/favicons?domain=novartis.com&sz=128" alt="Novartis"></div><div class="lr-name">Novartis</div></div>
        <div class="lr-item"><div class="lr-icon no-pad" style="background:#008CCE"><img src="https://www.google.com/s2/favicons?domain=abbott.com&sz=128" alt="Abbott"></div><div class="lr-name">Abbott Labs</div></div>
        <div class="lr-item"><div class="lr-icon no-pad" style="background:#C8A95A"><img src="https://www.google.com/s2/favicons?domain=elcompanies.com&sz=128" alt="Estée Lauder"></div><div class="lr-name">Estée Lauder</div></div>
        <div class="lr-item"><div class="lr-icon no-pad" style="background:#8E24AA"><img src="https://www.google.com/s2/favicons?domain=astrazeneca.com&sz=128" alt="AstraZeneca"></div><div class="lr-name">AstraZeneca</div></div>
        <div class="lr-item"><div class="lr-icon no-pad" style="background:#E31837"><img src="https://www.google.com/s2/favicons?domain=takeda.com&sz=128" alt="Takeda"></div><div class="lr-name">Takeda</div></div>
      </div>
      <div class="quotes-grid">
        <div class="q-card" onclick="toggleExpand(this)">
          <div class="q-mark">"</div>
          <div class="q-text">Among these five companies, I would definitely say Isomorphic Labs and Insilico Medicine would come out at the top. Isomorphic has multiple things under their control which keep them at the top.</div>
          <div class="q-extra">The combination of DeepMind's AI capabilities with deep biological domain expertise creates a unique advantage that no competitor can easily replicate. Their holistic approach to molecular modeling sets them apart.</div>
          <div class="q-author"><div class="q-avatar" style="background:linear-gradient(135deg,#635BFF,#80E9FF)">AB</div><div class="q-info"><h4>Former Head, Global Data Science CoE</h4><p>Abbott Laboratories</p></div></div>
        </div>
        <div class="q-card" onclick="toggleExpand(this)">
          <div class="q-mark">"</div>
          <div class="q-text">John Jumper brought accuracy up from 57% to 86%. Demis Hassabis also unorthodox. These two are outliers — rare talent not typically found in biopharma.</div>
          <div class="q-extra">The Nobel Prize recognition for AlphaFold validates the fundamental scientific breakthrough. This level of talent attraction is a significant competitive moat for the company.</div>
          <div class="q-author"><div class="q-avatar" style="background:linear-gradient(135deg,#24D164,#4ECDC4)">LY</div><div class="q-info"><h4>Senior Director, R&D Strategy</h4><p>Eli Lilly & Co</p></div></div>
        </div>
        <div class="q-card" onclick="toggleExpand(this)">
          <div class="q-mark">"</div>
          <div class="q-text">If we were to remove that they were a tech-first company, they are a true partner in the sense that we are co-developing assets with them. Our intention and hope is to go to market with them.</div>
          <div class="q-extra">Lilly views Isomorphic not as a vendor but as a strategic co-development partner with shared upside — a level of commitment that goes far beyond typical technology licensing.</div>
          <div class="q-author"><div class="q-avatar" style="background:linear-gradient(135deg,#E21937,#FF5CAA)">LY</div><div class="q-info"><h4>Sr. Director, AI & Accelerated Computing</h4><p>Eli Lilly & Co</p></div></div>
        </div>
      </div>
    </div>
  </div>

  <!-- INVESTMENT THESIS -->
  <div class="content-panel" data-node="thesis">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#635BFF,#80E9FF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Perspective</span><span class="bc-sep">›</span><span style="color:var(--accent)">Investment Thesis</span></div>
      <div class="label">Investment Thesis</div>
      <h2 class="sec-title">Why we believe in<br><span class="gradient-text">Isomorphic Labs</span></h2>
      <p class="sec-sub">A category-defining company with an amazing product in a market worth winning.</p>
      <div class="thesis-item" onclick="toggleExpand(this)"><div class="thesis-num">01</div><div><h3>Best-in-Class AI for Drug Discovery <span class="expand-icon">▾</span></h3><p>AlphaFold 2 achieved <strong>86% experimental accuracy</strong> in protein structure prediction — up from 40% prior state-of-art — declared "solved" by competition organizers.</p><div class="thesis-extra">Proprietary models (AlphaFold 2/3, Alpha Genome) represent a holistic approach using diffusion models to generate molecules satisfying all desired properties. This approach is fundamentally different and more powerful than the fragmented tools used by competitors.</div></div></div>
      <div class="thesis-item" onclick="toggleExpand(this)"><div class="thesis-num">02</div><div><h3>Massive Market Opportunity <span class="expand-icon">▾</span></h3><p>Global pharma R&D spend is <strong>$351B</strong> and growing, but productivity declining. Phase 2/3 timelines extended to 7.1 years while MOA exclusivity windows halved.</p><div class="thesis-extra">86% of clinical dev leaders face increased cost scrutiny — urgent demand for AI platforms. Drug discovery represents ~40% of drug development value, with the remaining 60% representing further expansion opportunity.</div></div></div>
      <div class="thesis-item" onclick="toggleExpand(this)"><div class="thesis-num">03</div><div><h3>Powerful Strategic Advantages <span class="expand-icon">▾</span></h3><p>Alphabet/DeepMind lineage provides unmatched talent — John Jumper (AlphaFold 2 inventor, Nobel Prize) and Demis Hassabis are "outliers — rare talent not found in biopharma."</p><div class="thesis-extra">Major pharma partnerships with Eli Lilly and Novartis validate platform quality. These partnerships provide both revenue and access to proprietary data that continuously improves the AI models.</div></div></div>
      <div class="thesis-item" onclick="toggleExpand(this)"><div class="thesis-num">04</div><div><h3>Clear Growth Levers <span class="expand-icon">▾</span></h3><p>Expansion from protein structure prediction → small molecule design → ADMET optimization → clinical pharmacology.</p><div class="thesis-extra">Platform potential across biologics (antibodies, ADCs). Shift from subscription to milestone- and royalty-based economics as pipeline matures. Proprietary pipeline creates asymmetric upside.</div></div></div>
    </div>
  </div>

  <!-- UNIQUE VALUE PROP -->
  <div class="content-panel" data-node="uvp">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#80E9FF,#635BFF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Perspective</span><span class="bc-sep">›</span><span style="color:#80E9FF">Unique Value Prop</span></div>
      <div class="label">Competitive Moat</div>
      <h2 class="sec-title">What sets Isomorphic apart</h2>
      <div class="data-table-wrap">
        <table class="data-table">
          <thead><tr><th style="width:200px">Dimension</th><th>Our Perspective</th><th>Market Commentary</th></tr></thead>
          <tbody>
            <tr><td class="em">DeepMind-Caliber AI</td><td>Foundation in AlphaFold, generalized to broader molecular modeling. Holistic diffusion-based approach. Trained on validated X-ray crystallography and NMR data.</td><td style="font-style:italic;color:var(--text3)">"Models are way ahead because they approach the entire problem holistically" — Abbott Labs</td></tr>
            <tr><td class="em">Pipeline Breadth</td><td>Spans target ID, hit finding, lead optimization, ADMET, binding dynamics, co-folding. Aspires to predict full clinical pharmacology.</td><td style="font-style:italic;color:var(--text3)">"Will aspire to predict affinities, clinical pharmacology, whole ADMET properties" — Eli Lilly</td></tr>
            <tr><td class="em">World-Class Team</td><td>Demis Hassabis (Nobel Prize) & John Jumper lead a team combining frontier AI + deep biology. Attracts top talent from both AI and biopharma.</td><td style="font-style:italic;color:var(--text3)">"These two are outliers — rare talent not typically found in biopharma" — Eli Lilly</td></tr>
            <tr><td class="em">Superior UX</td><td>Actionable insights for molecular screening, binding analysis, and target characterization with intuitive interface.</td><td style="font-style:italic;color:var(--text3)">"More user-friendly… saving a lot of time… giving us new chemical space" — Estée Lauder</td></tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>

  <!-- ELI LILLY PARTNERSHIP CASE STUDY -->
  <div class="content-panel" data-node="validation">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#E21937,#FF5CAA)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Perspective</span><span class="bc-sep">›</span><span style="color:#E21937">Partner Case Study</span></div>
      <div class="label">Partner Case Study</div>
      <h2 class="sec-title"><span style="display:inline-flex;align-items:center;gap:12px"><span class="lr-icon no-pad" style="background:#E21937;display:inline-flex;width:40px;height:40px;border-radius:10px"><img src="https://www.google.com/s2/favicons?domain=lilly.com&sz=128" alt="Eli Lilly"></span> Eli Lilly</span> — AI-Powered Co-Development</h2>
      <p class="sec-sub">Lilly's partnership with Isomorphic goes far beyond a technology platform deal — it is a deep scientific co-development with shared clinical upside.</p>
      <div class="data-table-wrap">
        <table class="data-table">
          <thead><tr><th style="width:160px">Dimension</th><th>Partner Insight</th></tr></thead>
          <tbody>
            <tr><td class="em">Partnership Model</td><td>Co-developing novel drug candidates together. <em>"If we were to remove that they were a tech-first company, they are a true partner — we are co-developing assets with them."</em> Intention to go to market jointly and share in the upside.</td></tr>
            <tr><td class="em">Strategic Rationale</td><td>Isomorphic finds novel molecular matter that traditional approaches cannot. Acts as both a complement and a backup — providing differentiated shots on goal beyond what Lilly's internal teams develop.</td></tr>
            <tr><td class="em">Scientific Depth</td><td>Not just technologists — Isomorphic performs in-vitro experimental validation alongside their models. Lilly pays for these services and for firewalling employees from competitors.</td></tr>
            <tr><td class="em">Data & IP</td><td>Isomorphic gains institutional knowledge from the partnership but does not train on Lilly's data. All partnership data stays with Lilly. No model advantage leakage to competitors.</td></tr>
            <tr><td class="em">Clinical Potential</td><td><em>"If anything we're collaborating on gets to Phase 1 it's an easy 5×. If anything gets to Phase 2 we would probably want to buy them."</em> Clinical milestones are the name of the game.</td></tr>
            <tr><td class="em">Market Context</td><td>Lilly is the <span class="hl">top spender on AI in pharma</span>. Taking GLP-1 winnings and partnering broadly to find the next franchise. AI in drug discovery is still unproven — but Isomorphic is the bet they're making.</td></tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>

  <!-- COMPETITIVE LANDSCAPE -->
  <div class="content-panel" data-node="competitive">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#FF5CAA,#635BFF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Perspective</span><span class="bc-sep">›</span><span style="color:#FF5CAA">Competitive Landscape</span></div>
      <div class="label">Competitive Landscape</div>
      <h2 class="sec-title">A crowded field — but<br>Isomorphic stands apart</h2>
      <p class="sec-sub">AI drug discovery has attracted $3B+ in venture capital since 2022. The landscape spans point-solution startups, AI-native biotechs, and infrastructure plays. Below is a comprehensive map of the competitive terrain.</p>

      <!-- KEY COMPETITOR PROFILES -->
      <h3 style="font-size:16px;font-family:var(--font-g);font-weight:700;margin:28px 0 6px;color:var(--text)">Key Competitor Profiles</h3>

      <div class="thesis-item" onclick="toggleExpand(this)" style="margin-bottom:8px">
        <div class="thesis-num" style="background:rgba(255,92,170,.08);color:#FF5CAA">
          <img src="https://www.google.com/s2/favicons?domain=cradle.bio&sz=64" alt="Cradle" style="width:18px;height:18px;border-radius:3px">
        </div>
        <div>
          <h3>Cradle — Protein Engineering Optimization <span class="expand-icon">&#9662;</span></h3>
          <p>Closed-loop protein and antibody lead optimization — a pharma team brings a defined target and initial molecule, and Cradle proposes optimized variants that are experimentally tested.</p>
          <div class="thesis-extra">Cradle is tightly coupled with wet-lab experimentation. Experimental data feeds back into the platform so models learn from each iteration. Designed to reduce time between optimization rounds and increase the likelihood that each iteration meaningfully improves potency, stability, and manufacturability. A <strong>convergence accelerator</strong> rather than a de novo design tool.</div>
        </div>
      </div>

      <div class="thesis-item" onclick="toggleExpand(this)" style="margin-bottom:8px">
        <div class="thesis-num" style="background:rgba(102,126,234,.08);color:#667eea">
          <img src="https://www.google.com/s2/favicons?domain=chaidiscovery.com&sz=64" alt="Chai" style="width:18px;height:18px;border-radius:3px">
        </div>
        <div>
          <h3>Chai Discovery — Early Discovery &amp; Hit Generation <span class="expand-icon">&#9662;</span></h3>
          <p>Molecular interaction modeling and generative biologics — focused on early discovery where little or no starting molecule exists.</p>
          <div class="thesis-extra">Chai generates candidate binders or interaction hypotheses from biological targets, accelerating the transition from biological hypothesis to viable starting molecules. Its value lies at the <strong>front of the discovery funnel</strong> — increasing the speed and breadth of early exploration rather than optimizing known leads.</div>
        </div>
      </div>

      <!-- FULL LANDSCAPE TABLE -->
      <h3 style="font-size:16px;font-family:var(--font-g);font-weight:700;margin:28px 0 6px;color:var(--text)">Full Competitive Map</h3>
      <p style="font-size:12px;color:var(--text3);margin-bottom:12px">Sorted by funding raised. Pipeline stages color-coded to the drug development lifecycle.</p>

      <div class="data-table-wrap">
        <table class="data-table" style="font-size:12px;table-layout:fixed;width:100%">
          <colgroup>
            <col style="width:18%">
            <col style="width:5%">
            <col style="width:22%">
            <col style="width:37%">
            <col style="width:10%">
            <col style="width:8%">
          </colgroup>
          <thead>
            <tr><th>Company</th><th>Est.</th><th>Pipeline Stage</th><th>Specific Edge</th><th>Raised</th><th>Team</th></tr>
          </thead>
          <tbody>
            <tr>
              <td class="em">Xaira Therapeutics</td>
              <td>2024</td>
              <td><span class="stage-tag stage-e2e">End-to-end</span></td>
              <td>AI-native biotech integrating AI across discovery and early development for internal programs</td>
              <td class="em">~$1B+</td>
              <td>190</td>
            </tr>
            <tr>
              <td class="em">Formation Bio</td>
              <td>2016</td>
              <td><span class="stage-tag stage-disc">Discovery</span> <span class="stage-tag stage-clin">Clinical</span></td>
              <td>AI discovery paired with in-house drug development, advancing assets through clinical stages</td>
              <td class="em">~$600M+</td>
              <td>200</td>
            </tr>
            <tr>
              <td class="em">Lila Sciences</td>
              <td>2023</td>
              <td><span class="stage-tag stage-disc">Discovery</span> <span class="stage-tag stage-lead">Lead Opt.</span></td>
              <td>AI models + large-scale automated wet labs generating proprietary data for iterative refinement</td>
              <td class="em">$550M</td>
              <td>260</td>
            </tr>
            <tr>
              <td class="em">Genesis Therapeutics</td>
              <td>2019</td>
              <td><span class="stage-tag stage-hit">Hit ID</span> <span class="stage-tag stage-lead">Lead Opt.</span></td>
              <td>Physics-aware ML for small-molecule design on difficult targets using biophysical constraints</td>
              <td class="em">$250M</td>
              <td>150</td>
            </tr>
            <tr>
              <td class="em">Profluent Bio</td>
              <td>2022</td>
              <td><span class="stage-tag stage-disc">Discovery</span> <span class="stage-tag stage-hit">Hit ID</span></td>
              <td>Large generative protein models to design novel sequences beyond known scaffolds</td>
              <td class="em">~$150M</td>
              <td>50</td>
            </tr>
            <tr>
              <td class="em">Medra AI</td>
              <td>2025</td>
              <td><span class="stage-tag stage-hit">Hit ID</span></td>
              <td>Autonomous small-molecule discovery loops combining AI with robotic wet-lab execution</td>
              <td class="em">$82M</td>
              <td>5</td>
            </tr>
            <tr>
              <td class="em">Edison Scientific</td>
              <td>2025</td>
              <td><span class="stage-tag stage-disc">Discovery</span></td>
              <td>Discovery support and hypothesis generation</td>
              <td class="em">$70M</td>
              <td>45</td>
            </tr>
            <tr>
              <td class="em">Manas AI</td>
              <td>2023</td>
              <td><span class="stage-tag stage-disc">Discovery</span> <span class="stage-tag stage-preclin">Preclinical</span></td>
              <td>Rapidly designs and advances internal therapeutic programs — asset creation over software</td>
              <td class="em">$50M</td>
              <td>16</td>
            </tr>
            <tr>
              <td class="em">Latent Labs</td>
              <td>2023</td>
              <td><span class="stage-tag stage-disc">Discovery</span></td>
              <td>Frontier models for discovery support and hypothesis generation</td>
              <td class="em">$50M</td>
              <td>20</td>
            </tr>
            <tr>
              <td class="em">Collate</td>
              <td>2025</td>
              <td><span class="stage-tag stage-infra">Infrastructure</span></td>
              <td>Data management, experiment tracking, and workflow tooling for AI-native biotech</td>
              <td>$30M</td>
              <td>23</td>
            </tr>
            <tr>
              <td class="em">Axiom AI</td>
              <td>2024</td>
              <td><span class="stage-tag stage-infra">Infrastructure</span></td>
              <td>Compute, analytics, and experimentation infrastructure for AI-driven biology</td>
              <td>$30M</td>
              <td>23</td>
            </tr>
            <tr>
              <td class="em">Boltz Bio</td>
              <td>2025</td>
              <td><span class="stage-tag stage-hit">Hit ID</span> <span class="stage-tag stage-lead">Lead Opt.</span></td>
              <td>Biophysical modeling + ML for molecule design with structural and binding constraints</td>
              <td>$28M</td>
              <td>6</td>
            </tr>
            <tr>
              <td class="em">Ataraxis AI</td>
              <td>2023</td>
              <td><span class="stage-tag stage-disc">Discovery</span></td>
              <td>Predictive models for molecular and biological outcomes across discovery workflows</td>
              <td>$24M</td>
              <td>36</td>
            </tr>
            <tr>
              <td class="em">Valinor Discovery</td>
              <td>2024</td>
              <td><span class="stage-tag stage-hit">Hit ID</span></td>
              <td>AI small-molecule discovery grounded in biological context and target relevance</td>
              <td>$13M</td>
              <td>12</td>
            </tr>
            <tr>
              <td class="em">Numenos AI</td>
              <td>2023</td>
              <td><span class="stage-tag stage-hit">Hit ID</span></td>
              <td>Early-stage molecular design models for initial hit generation and prioritization</td>
              <td>$8M</td>
              <td>14</td>
            </tr>
          </tbody>
        </table>
      </div>

      <!-- STAGE TAG LEGEND -->
      <div style="display:flex;flex-wrap:wrap;gap:6px;margin-top:10px;padding:8px 0">
        <span style="font-size:10px;color:var(--text3);margin-right:4px;line-height:20px">Stages:</span>
        <span class="stage-tag stage-disc">Discovery</span>
        <span class="stage-tag stage-tgtval">Target Val.</span>
        <span class="stage-tag stage-hit">Hit ID</span>
        <span class="stage-tag stage-lead">Lead Opt.</span>
        <span class="stage-tag stage-preclin">Preclinical</span>
        <span class="stage-tag stage-clin">Clinical</span>
        <span class="stage-tag stage-e2e">End-to-end</span>
        <span class="stage-tag stage-infra">Infrastructure</span>
      </div>

      <!-- ISOMORPHIC DIFFERENTIATION -->
      <div style="background:rgba(99,91,255,.04);border:1px solid rgba(99,91,255,.12);border-radius:12px;padding:20px 24px;margin-top:24px">
        <h3 style="font-size:14px;font-family:var(--font-g);font-weight:700;margin:0 0 8px;color:var(--accent)">Why Isomorphic Is Different</h3>
        <div style="display:grid;grid-template-columns:1fr 1fr;gap:12px;font-size:12px;color:var(--text2)">
          <div><strong style="color:var(--text)">Full-stack, not point-solution.</strong> Most competitors address one stage of discovery. Isomorphic spans target ID through lead optimization with integrated models.</div>
          <div><strong style="color:var(--text)">DeepMind lineage.</strong> All new foundational AI models from DeepMind flow directly to Isomorphic — no other startup has this pipeline of frontier research.</div>
          <div><strong style="color:var(--text)">Alphabet compute.</strong> Access to Google's infrastructure provides a durable data and compute moat that venture-funded competitors cannot replicate.</div>
          <div><strong style="color:var(--text)">Co-development, not SaaS.</strong> Lilly and Novartis partnerships are joint drug programs with shared clinical upside — not software licenses or service contracts.</div>
        </div>
      </div>
    </div>
  </div>

  <!-- GROWTH OPPORTUNITIES -->
  <div class="content-panel" data-node="growth">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#24D164,#80E9FF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Perspective</span><span class="bc-sep">›</span><span style="color:#24D164">Growth Vectors</span></div>
      <div class="label">Growth Vectors</div>
      <h2 class="sec-title">Significant growth<br>opportunities lie ahead</h2>

      <!-- Drug Discovery Pipeline Timeline -->
      <h3 style="font-size:18px;font-family:var(--font-g);font-weight:700;margin:32px 0 8px">Drug Discovery Pipeline</h3>
      <p style="font-size:13px;color:var(--text3);margin-bottom:16px">Current capabilities and expansion roadmap</p>
      <div class="pipeline">
        <div class="pipeline-stage pl-active"><div class="pipeline-node">1</div><h4>Target ID</h4><p>AlphaFold structure prediction</p></div>
        <div class="pipeline-stage pl-active"><div class="pipeline-node">2</div><h4>Hit Finding</h4><p>Molecular screening & generation</p></div>
        <div class="pipeline-stage pl-active"><div class="pipeline-node">3</div><h4>Lead Optimization</h4><p>Property optimization</p></div>
        <div class="pipeline-stage pl-active"><div class="pipeline-node">4</div><h4>ADMET</h4><p>Absorption, distribution, metabolism</p></div>
        <div class="pipeline-stage pl-future"><div class="pipeline-node">5</div><h4>Clinical Pharm</h4><p>Digital twins, trial design</p></div>
      </div>

      <div style="margin-top:40px">
        <div class="thesis-item" onclick="toggleExpand(this)"><div class="thesis-num" style="background:rgba(128,233,255,.1);color:var(--accent2)">→</div><div><h3>Platform Expansion <span class="expand-icon">▾</span></h3><p>Expand from small molecules into <strong>biologics</strong> (antibodies, ADCs, immunotherapies) — the largest and fastest-growing segments.</p><div class="thesis-extra">Multi-modal AI combining structural biology, genomics, multi-omics, and real-world evidence. Drug development (60% of total value) remains largely unaddressed — opportunity for digital twins and trial optimization.</div></div></div>
        <div class="thesis-item" onclick="toggleExpand(this)"><div class="thesis-num" style="background:rgba(36,209,100,.1);color:var(--green)">→</div><div><h3>Pharma Partnership Expansion <span class="expand-icon">▾</span></h3><p>Deepen existing Eli Lilly & Novartis deals — expanded therapeutic areas, milestone/royalty triggers.</p><div class="thesis-extra">Partnerships provide dual advantage: AI tech stack access for pharma + proprietary wet/dry lab data that improves models. M&A structures shifting to smaller, milestone-heavy transactions — perfectly aligned.</div></div></div>
        <div class="thesis-item" onclick="toggleExpand(this)"><div class="thesis-num" style="background:rgba(255,92,170,.1);color:var(--pink)">→</div><div><h3>Proprietary Pipeline Optionality <span class="expand-icon">▾</span></h3><p>Internal drug candidates create <strong>asymmetric upside</strong>. Precedent EV for "very good quality" Phase 3 assets has <strong>doubled since 2021 to $3.4B</strong>.</p><div class="thesis-extra">Modality acquisition precedents: Gilead/Kite $11.9B, Novartis/AveXis $8.7B, Celgene/Juno $9B.</div></div></div>
        <div class="thesis-item" onclick="toggleExpand(this)"><div class="thesis-num" style="background:rgba(255,122,0,.1);color:var(--orange)">→</div><div><h3>Technical Moat Deepening <span class="expand-icon">▾</span></h3><p>All new DeepMind AI models flow to Isomorphic. Feedback loops from pharma partnerships accelerate model improvement.</p><div class="thesis-extra">The ultimate differentiator: clinical outcomes — "90% of drug candidates fail. What will differentiate is whenever a candidate survives rigorous clinical development with more approvals."</div></div></div>
      </div>
    </div>
  </div>

  <!-- RISKS & MITIGANTS -->
  <div class="content-panel" data-node="risks">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#FF7A00,#FF4D6D)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Perspective</span><span class="bc-sep">›</span><span style="color:#FF7A00">Risks & Mitigants</span></div>
      <div class="label">Key Risks & Mitigants</div>
      <h2 class="sec-title">Balanced perspective</h2>
      <div class="data-table-wrap">
        <div class="risk-row"><div class="risk-cell"><strong>Clinical Validation Pending</strong>90% of drug candidates fail; Isomorphic still preclinical while Insilico is in clinical trials</div><div class="risk-cell">Fundamentally deeper modeling approach should translate to better clinical success. Lilly/Novartis partnerships provide resources and data to accelerate.</div></div>
        <div class="risk-row"><div class="risk-cell"><strong>End-to-End Gap</strong>Drug discovery is ~40% of value; development (60%) not yet addressed</div><div class="risk-cell">Clear roadmap into multi-omics, RWE, digital twins. Complementary partnerships (e.g., Unlearn.ai) could accelerate.</div></div>
        <div class="risk-row"><div class="risk-cell"><strong>Competitive Intensity</strong>Multiple well-funded AI companies; pharma building in-house</div><div class="risk-cell">Expert consensus ranks Isomorphic #1 for small molecules. DeepMind talent + Alphabet compute are durable moats. Only 15% of pharma has AI in full rollout.</div></div>
        <div class="risk-row"><div class="risk-cell"><strong>Revenue Model Maturity</strong>Subscription revenue is early; pipeline economics years away</div><div class="risk-cell">Partnership milestones with Lilly/Novartis provide near-term revenue. De-risked Phase 3 assets valued at $3.4B — each successful program is transformative.</div></div>
      </div>
    </div>
  </div>

  <!-- STRIPES OVERVIEW -->
  <div class="content-panel" data-node="team">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#635BFF,#80E9FF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Team</span><span class="bc-sep">›</span><span style="color:var(--accent)">Stripes Overview</span></div>
      <div class="label">Stripes Overview</div>
      <h2 class="sec-title">We help teams with amazing products<br>build categories that matter</h2>
      <p class="sec-sub">Founded in 2008 with a mission to invest in best-in-class technology and consumer products. Based in NYC, investing globally with $8B AUM.</p>

      <!-- Investment Timeline -->
      <h3 style="font-size:18px;font-family:var(--font-g);font-weight:700;margin:32px 0 16px">Key Portfolio Milestones</h3>
      <div class="timeline" id="investTimeline">
        <div class="timeline-item"><div class="tl-date">Series C Lead</div><h4>monday.com</h4><p>Brand marketing strategy, IPO preparation → NASDAQ: MNDY, <strong style="color:var(--accent)">$14.9B</strong> market cap</p></div>
        <div class="timeline-item"><div class="tl-date">First Institutional Investor</div><h4>On Running</h4><p>eCommerce optimization, strategic intros → NYSE: ONON, <strong style="color:var(--accent)">$19.5B</strong> market cap</p></div>
        <div class="timeline-item"><div class="tl-date">Led $225M Round</div><h4>A24</h4><p>Category-defining entertainment brand → Private valuation: <strong style="color:var(--accent)">$3.5B+</strong></p></div>
      </div>

      <div class="partner-grid">
        <div class="p-card" onclick="toggleExpand(this)">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#6161FF"><img src="https://www.google.com/s2/favicons?domain=monday.com&sz=128" alt="monday.com"></div><div class="name">monday.com</div></div>
          <div class="type">Led Series C → NASDAQ: MNDY</div>
          <div class="desc">Brand marketing strategy, financial reporting best practices, IPO preparation. Current market cap: <strong style="color:var(--text)">$14.9B</strong></div>
          <div class="p-extra">Stripes helped monday.com refine their brand positioning and prepared the company for its successful IPO. Our Scale Team provided direct support on financial reporting and investor relations.</div>
        </div>
        <div class="p-card" onclick="toggleExpand(this)">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#000;border:1px solid #444"><img src="https://www.google.com/s2/favicons?domain=on-running.com&sz=128" alt="On Running"></div><div class="name">On Running</div></div>
          <div class="type">First Institutional Investor → NYSE: ONON</div>
          <div class="desc">eCommerce optimization, strategic intros (Equinox, Nordstrom), Hillhouse Capital intro for Asia. Current market cap: <strong style="color:var(--text)">$19.5B</strong></div>
          <div class="p-extra">As the first institutional investor, Stripes provided foundational support including eCommerce strategy, key retail partnerships, and introductions to expand into Asian markets.</div>
        </div>
        <div class="p-card" onclick="toggleExpand(this)">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#000;border:1px solid #444"><img src="https://www.google.com/s2/favicons?domain=a24films.com&sz=128" alt="A24"></div><div class="name">A24</div></div>
          <div class="type">Led $225M Round</div>
          <div class="desc">Category-defining entertainment brand. Private valuation: <strong style="color:var(--text)">$3.5B+</strong></div>
          <div class="p-extra">A24 exemplifies our philosophy of investing in category-defining companies with unique brand identity and deep cultural resonance.</div>
        </div>
      </div>
    </div>
  </div>

  <!-- SCALE TEAM -->
  <div class="content-panel" data-node="scaleteam">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#24D164,#80E9FF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Team</span><span class="bc-sep">›</span><span style="color:#24D164">Scale Team</span></div>
      <div class="label">Scale Team</div>
      <h2 class="sec-title">Dedicated operating resources<br>to help Isomorphic <span class="gradient-text">scale faster</span></h2>
      <p class="sec-sub">Stripes' in-house Scale Team provides hands-on support across every critical function — not just capital, but execution firepower embedded alongside your team.</p>

      <div class="scale-grid-3" style="gap:16px;margin-top:32px">
        <div style="background:rgba(99,91,255,.06);border-radius:14px;padding:20px;border:1px solid rgba(99,91,255,.08)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:14px;color:var(--accent);margin-bottom:8px">Talent</div>
          <p style="font-size:13px;color:var(--text2);line-height:1.5;margin:0">Executive search, org design, compensation benchmarking, employer branding</p>
        </div>
        <div style="background:rgba(36,209,100,.06);border-radius:14px;padding:20px;border:1px solid rgba(36,209,100,.08)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:14px;color:var(--green);margin-bottom:8px">Marketing & Brand</div>
          <p style="font-size:13px;color:var(--text2);line-height:1.5;margin:0">Brand positioning, content strategy, demand generation, event marketing</p>
        </div>
        <div style="background:rgba(255,122,0,.06);border-radius:14px;padding:20px;border:1px solid rgba(255,122,0,.08)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:14px;color:var(--orange);margin-bottom:8px">Finance & Legal</div>
          <p style="font-size:13px;color:var(--text2);line-height:1.5;margin:0">FP&A setup, audit readiness, legal counsel, entity structuring, tax strategy</p>
        </div>
        <div style="background:rgba(128,233,255,.06);border-radius:14px;padding:20px;border:1px solid rgba(128,233,255,.08)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:14px;color:#0CB7D6;margin-bottom:8px">Data & Analytics</div>
          <p style="font-size:13px;color:var(--text2);line-height:1.5;margin:0">Data infrastructure, KPI dashboards, customer analytics, pricing optimization</p>
        </div>
        <div style="background:rgba(255,92,170,.06);border-radius:14px;padding:20px;border:1px solid rgba(255,92,170,.08)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:14px;color:#FF5CAA;margin-bottom:8px">Growth & Sales</div>
          <p style="font-size:13px;color:var(--text2);line-height:1.5;margin:0">GTM strategy, enterprise sales playbooks, pipeline management, partnership sourcing</p>
        </div>
        <div style="background:rgba(200,169,90,.06);border-radius:14px;padding:20px;border:1px solid rgba(200,169,90,.08)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:14px;color:var(--gold);margin-bottom:8px">Operations</div>
          <p style="font-size:13px;color:var(--text2);line-height:1.5;margin:0">Procurement, vendor management, international expansion, systems & process design</p>
        </div>
      </div>

      <h3 style="font-size:18px;font-family:var(--font-g);font-weight:700;margin:40px 0 16px">Immediate Value-Add for Isomorphic Labs</h3>
      <div class="scale-grid-2" style="gap:14px">
        <div style="background:rgba(99,91,255,.04);border-radius:12px;padding:16px 20px;border-left:3px solid var(--accent)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:13px;margin-bottom:6px">Enterprise GTM Buildout</div>
          <p style="font-size:12.5px;color:var(--text2);line-height:1.5;margin:0">Help design and staff the enterprise sales motion for pharma partnerships — including territory planning, pricing strategy, and customer success frameworks</p>
        </div>
        <div style="background:rgba(99,91,255,.04);border-radius:12px;padding:16px 20px;border-left:3px solid var(--green)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:13px;margin-bottom:6px">Executive Talent Pipeline</div>
          <p style="font-size:12.5px;color:var(--text2);line-height:1.5;margin:0">Source and recruit senior commercial leaders with pharma/biotech experience — CRO, VP Sales, Head of Partnerships — through our proprietary network</p>
        </div>
        <div style="background:rgba(99,91,255,.04);border-radius:12px;padding:16px 20px;border-left:3px solid var(--orange)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:13px;margin-bottom:6px">Pharma Customer Intros</div>
          <p style="font-size:12.5px;color:var(--text2);line-height:1.5;margin:0">Leverage advisory council relationships to open doors at top 20 pharma — warm intros to R&D decision-makers and Chief Digital Officers</p>
        </div>
        <div style="background:rgba(99,91,255,.04);border-radius:12px;padding:16px 20px;border-left:3px solid #FF5CAA">
          <div style="font-family:var(--font-g);font-weight:700;font-size:13px;margin-bottom:6px">Brand & Thought Leadership</div>
          <p style="font-size:12.5px;color:var(--text2);line-height:1.5;margin:0">Position Isomorphic as the category leader in AI drug discovery — conference strategy, media relations, case study development, and analyst engagement</p>
        </div>
      </div>
    </div>
  </div>

  <!-- HEALTHCARE EXPERTISE -->
  <div class="content-panel" data-node="healthcare">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#FF6B9D,#FF5CAA)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Team</span><span class="bc-sep">›</span><span style="color:#FF6B9D">Healthcare Expertise</span></div>
      <div class="label">Healthcare Expertise</div>
      <h2 class="sec-title">Deep experience in<br><span class="gradient-text">healthcare & life sciences</span></h2>
      <p class="sec-sub">Healthcare is a core vertical for Stripes. We've built category leaders across pharma services, health tech, clinical analytics, and digital health — giving us pattern recognition directly relevant to Isomorphic.</p>

      <div class="partner-grid partner-grid--single" style="gap:16px;margin-top:24px">
        <div class="p-card" onclick="toggleExpand(this)" style="padding:20px">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#1D71B8"><img src="https://www.google.com/s2/favicons?domain=flatiron.com&sz=128" alt="Flatiron Health"></div><div class="name">Flatiron Health</div></div>
          <div class="type">Oncology SaaS & Real-World Evidence • Acquired by Roche for $2.1B</div>
          <div class="desc">Placed CFO, Chief People Officer, IPO Controller; intros into RCM and RWE businesses. <strong style="color:var(--green)">$29M → $90M ARR (57% CAGR)</strong></div>
          <div class="p-extra">Stripes placed three C-suite executives and provided strategic introductions that helped Flatiron scale its real-world evidence platform, ultimately leading to Roche's $2.1B acquisition. Directly relevant to Isomorphic as a pharma platform company that scaled into enterprise deals with large pharma.</div>
        </div>
        <div class="p-card" onclick="toggleExpand(this)" style="padding:20px">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#FF6B9D"><img src="https://www.google.com/s2/favicons?domain=pomelocare.com&sz=128" alt="Pomelo Care"></div><div class="name">Pomelo Care</div></div>
          <div class="type">Virtual Maternal Care Platform</div>
          <div class="desc">Advised on performance marketing, strategy to expand to Medicare/Commercial. <strong style="color:var(--green)">$11M → $66M revenue run rate (230% CAGR)</strong></div>
          <div class="p-extra">Our Scale Team connected Pomelo with payer network contacts and helped design their expansion strategy into Medicare and commercial insurance markets.</div>
        </div>
        <div class="p-card" onclick="toggleExpand(this)" style="padding:20px">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#6C63FF"><img src="https://www.google.com/s2/favicons?domain=equip.health&sz=128" alt="Equip"></div><div class="name">Equip</div></div>
          <div class="type">Virtual Eating Disorder Treatment</div>
          <div class="desc">Evidence-based, family-centered eating disorder treatment delivered via telehealth. Rapid scale through payer partnerships and clinical outcomes data.</div>
          <div class="p-extra">Equip demonstrates Stripes' ability to scale digital health platforms that require clinical rigor, payer contracting, and evidence-based validation — capabilities directly transferable to Isomorphic's pharma engagement model.</div>
        </div>
        <div class="p-card" onclick="toggleExpand(this)" style="padding:20px">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#2B7A78"><img src="https://www.google.com/s2/favicons?domain=boulder.care&sz=128" alt="Boulder Care"></div><div class="name">Boulder Care</div></div>
          <div class="type">Virtual Addiction Medicine</div>
          <div class="desc">Tech-enabled substance use disorder treatment platform. Scaled through Medicaid and commercial payer partnerships.</div>
          <div class="p-extra">Boulder's model of using technology to improve clinical outcomes in a highly regulated environment mirrors the challenges Isomorphic faces in gaining pharma trust and regulatory acceptance.</div>
        </div>
        <div class="p-card" onclick="toggleExpand(this)" style="padding:20px">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#E8475F"><img src="https://www.google.com/s2/favicons?domain=helloheart.com&sz=128" alt="Hello Heart"></div><div class="name">Hello Heart</div></div>
          <div class="type">Digital Cardiovascular Health</div>
          <div class="desc">AI-powered heart health platform with clinically validated outcomes. Deployed through employer and health plan channels.</div>
          <div class="p-extra">Hello Heart's combination of AI/ML-driven insights with clinical validation is a strong parallel to Isomorphic's approach — both require rigorous evidence to win enterprise healthcare buyers.</div>
        </div>
        <div class="p-card" onclick="toggleExpand(this)" style="padding:20px">
          <div class="p-card-head"><div class="lr-icon no-pad" style="background:#1A3C5E"><img src="https://www.google.com/s2/favicons?domain=chapter.com&sz=128" alt="Chapter"></div><div class="name">Chapter</div></div>
          <div class="type">Medicare Advisory Platform</div>
          <div class="desc">Tech-enabled Medicare advisory helping seniors navigate plan selection. Scaled through direct-to-consumer and B2B2C channels.</div>
          <div class="p-extra">Chapter shows Stripes' expertise in scaling healthcare platforms that require deep domain knowledge, regulatory navigation, and trust-building — all relevant to Isomorphic's pharma engagement.</div>
        </div>
      </div>

      <div style="background:rgba(255,107,157,.04);border-radius:12px;padding:16px 20px;margin-top:24px;border:1px solid rgba(255,107,157,.06)">
        <p style="font-size:12.5px;color:var(--text2);line-height:1.6;margin:0"><strong style="color:var(--text)">Pattern recognition:</strong> Across these investments we've learned how to sell complex technology platforms into pharma R&D organizations — long sales cycles, multi-stakeholder buying committees, compliance requirements, and the importance of clinical validation.</p>
      </div>

      <!-- HEALTHCARE NETWORK -->
      <h3 style="font-size:16px;font-family:var(--font-g);font-weight:700;margin:32px 0 6px;color:var(--text)">Healthcare Network</h3>
      <p style="font-size:12px;color:var(--text3);margin-bottom:14px">Senior leaders across pharma, health systems, payers, and life sciences — available to Isomorphic through our advisory councils and executive advisor network.</p>

      <div class="data-table-wrap">
        <table class="data-table" style="font-size:12px;table-layout:fixed;width:100%">
          <colgroup><col style="width:22%"><col style="width:30%"><col style="width:28%"><col style="width:20%"></colgroup>
          <thead><tr><th>Name</th><th>Company</th><th>Role</th><th>Resource</th></tr></thead>
          <tbody>
            <tr><td class="em">Greg Meyers</td><td>Bristol Myers Squibb</td><td>Chief Digital & Technology Officer</td><td><span class="stage-tag stage-hit" style="font-size:9px">Tech Council</span></td></tr>
            <tr><td class="em">Jim Swanson</td><td>Johnson & Johnson</td><td>Global CIO</td><td><span class="stage-tag stage-hit" style="font-size:9px">Tech Council</span></td></tr>
            <tr><td class="em">Ryan Snyder</td><td>Thermo Fisher Scientific</td><td>SVP & CIO</td><td><span class="stage-tag stage-hit" style="font-size:9px">Tech Council</span></td></tr>
            <tr><td class="em">Jorge Populo</td><td>UnitedHealth Group</td><td>CIO</td><td><span class="stage-tag stage-hit" style="font-size:9px">Tech Council</span></td></tr>
            <tr><td class="em">Michelle Greene</td><td>Cardinal Health</td><td>Global CIO</td><td><span class="stage-tag stage-hit" style="font-size:9px">Tech Council</span></td></tr>
            <tr><td class="em">BJ Moore</td><td>Providence Healthcare</td><td>Former CIO</td><td><span class="stage-tag stage-hit" style="font-size:9px">Tech Council</span></td></tr>
            <tr><td class="em">Daniel Barchi</td><td>CommonSpirit</td><td>CIO</td><td><span class="stage-tag stage-hit" style="font-size:9px">Tech Council</span></td></tr>
            <tr><td class="em">Aimee Cardwell</td><td>UnitedHealth Group</td><td>Former EVP & CISO</td><td><span class="stage-tag stage-lead" style="font-size:9px">CISO Council</span></td></tr>
            <tr><td class="em">James Beeson</td><td>Cigna</td><td>Former CISO</td><td><span class="stage-tag stage-lead" style="font-size:9px">CISO Council</span></td></tr>
            <tr><td class="em">Nick Vigier</td><td>Oscar Health</td><td>CISO</td><td><span class="stage-tag stage-lead" style="font-size:9px">CISO Council</span></td></tr>
            <tr><td class="em">Tiffany Inglis</td><td>Sera Prognostics</td><td>Chief Medical Officer</td><td><span class="stage-tag stage-disc" style="font-size:9px">Exec. Advisor</span></td></tr>
            <tr><td class="em">David Weathington</td><td>Elevance</td><td>VP, Network & Value Based Solutions</td><td><span class="stage-tag stage-disc" style="font-size:9px">Exec. Advisor</span></td></tr>
            <tr><td class="em">Mike Bowersox</td><td>Humana</td><td>Former Medicare President, Mid-Atlantic</td><td><span class="stage-tag stage-disc" style="font-size:9px">Exec. Advisor</span></td></tr>
            <tr><td class="em">Michelle Carnahan</td><td>Thirty Madison</td><td>President</td><td><span class="stage-tag stage-disc" style="font-size:9px">Exec. Advisor</span></td></tr>
            <tr><td class="em">Jason Parrot</td><td>Vida</td><td>SVP Enterprise Growth & Partnerships</td><td><span class="stage-tag stage-disc" style="font-size:9px">Exec. Advisor</span></td></tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>

  <!-- OUR NETWORK (Operating Partners + Sr. Advisors + Councils) -->
  <div class="content-panel" data-node="ops">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#80E9FF,#635BFF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Team</span><span class="bc-sep">›</span><span style="color:#80E9FF">Our Network</span></div>
      <div class="label">Our Network</div>
      <h2 class="sec-title">Dedicated operating resources<br>to help Isomorphic <span class="gradient-text">scale faster</span></h2>
      <p class="sec-sub">Operating Partners work hands-on with portfolio companies. Senior Advisors and Council members provide strategic access to decision-makers across healthcare, technology, and enterprise leadership.</p>

      <div style="background:rgba(99,91,255,.04);border-radius:12px;padding:16px 20px;margin-top:20px;border:1px solid rgba(99,91,255,.06)">
        <p style="font-size:12.5px;color:var(--text2);line-height:1.6;margin:0"><strong style="color:var(--text)">For Isomorphic:</strong> Our Tech Council and CISO Council include technology decision-makers at major pharma and healthcare companies (BMS, J&J, Thermo Fisher, UnitedHealth, Cardinal Health). These relationships provide warm introductions to prospective customers and give Isomorphic a direct line to the buyers who control AI procurement budgets.</p>
      </div>

      <!-- OPERATING PARTNERS -->
      <h3 style="font-size:15px;font-family:var(--font-g);font-weight:700;margin:28px 0 4px;color:var(--accent)">Operating Partners</h3>
      <p style="font-size:12px;color:var(--text3);margin-bottom:14px">Embedded C-suite operators — not just advisory, but hands-on execution support.</p>

      <div class="data-table-wrap">
        <table class="data-table" style="font-size:12px;table-layout:fixed;width:100%">
          <colgroup><col style="width:22%"><col style="width:28%"><col style="width:50%"></colgroup>
          <thead><tr><th>Name</th><th>Background</th><th>Isomorphic Relevance</th></tr></thead>
          <tbody>
            <tr><td class="em">Paul Melchiorre</td><td>Former CRO, Anaplan</td><td>Enterprise sales motion — territory planning, pricing, repeatable large-deal playbooks</td></tr>
            <tr><td class="em">Scott Aronson</td><td>Former COO, Cloudera</td><td>Platform-as-a-service GTM — transitioning custom engagements to scalable offerings</td></tr>
            <tr><td class="em">Jindra Zitek</td><td>Former CIO, Chobani</td><td>Data infrastructure at scale — pharma-grade datasets, compliance, secure compute</td></tr>
            <tr><td class="em">Sharon Rothstein</td><td>Former Global CMO, Starbucks</td><td>Category leadership positioning — establishing Isomorphic as the definitive AI discovery platform</td></tr>
            <tr><td class="em">Mike Vaughan</td><td>Former COO, Venmo</td><td>Operational scaling — systems and processes to support rapid headcount and revenue growth</td></tr>
            <tr><td class="em">Julie Herendeen</td><td>Former CMO, Dropbox</td><td>Growth marketing — driving awareness and pipeline within pharma/biotech buyers</td></tr>
          </tbody>
        </table>
      </div>

      <!-- SENIOR ADVISORS -->
      <h3 style="font-size:15px;font-family:var(--font-g);font-weight:700;margin:28px 0 4px;color:var(--green)">Senior Advisors</h3>
      <p style="font-size:12px;color:var(--text3);margin-bottom:14px">Former C-suite executives providing strategic guidance and board-level relationships.</p>

      <div class="data-table-wrap">
        <table class="data-table" style="font-size:12px;table-layout:fixed;width:100%">
          <colgroup><col style="width:25%"><col style="width:35%"><col style="width:40%"></colgroup>
          <thead><tr><th>Name</th><th>Background</th><th>Relevance</th></tr></thead>
          <tbody>
            <tr><td class="em">David Swinghamer</td><td>Former CEO, Shake Shack</td><td>CEO-level operational scaling and public company leadership</td></tr>
            <tr><td class="em">Harry Moseley</td><td>Former CIO, Zoom</td><td>Enterprise technology deployment and global IT strategy</td></tr>
            <tr><td class="em">John Kinzer</td><td>Former CFO, HubSpot</td><td>SaaS financial modeling, IPO readiness, and growth-stage finance</td></tr>
            <tr><td class="em">Michael Nolan</td><td>Former VP Global Real Estate, Amazon</td><td>Large-scale infrastructure and facilities strategy</td></tr>
          </tbody>
        </table>
      </div>

      <!-- ADVISORY COUNCILS -->
      <h3 style="font-size:15px;font-family:var(--font-g);font-weight:700;margin:28px 0 4px;color:#FF5CAA">Advisory Councils</h3>
      <p style="font-size:12px;color:var(--text3);margin-bottom:14px">Specialized councils of senior executives — direct access to decision-makers who can open doors and validate strategy.</p>

      <div style="display:grid;grid-template-columns:1fr 1fr;gap:12px;margin-bottom:16px">
        <div style="background:rgba(99,91,255,.04);border-radius:12px;padding:16px;border:1px solid rgba(99,91,255,.06)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:13px;margin-bottom:8px;color:var(--accent)">Tech Council <span style="font-weight:400;font-size:11px;color:var(--text3)">(27 members)</span></div>
          <div style="font-size:11px;color:var(--text2);line-height:1.7">
            <div><strong>Greg Meyers</strong> — CDTO, Bristol Myers Squibb</div>
            <div><strong>Jim Swanson</strong> — Global CIO, Johnson & Johnson</div>
            <div><strong>Ryan Snyder</strong> — SVP & CIO, Thermo Fisher Scientific</div>
            <div><strong>Jorge Populo</strong> — CIO, UnitedHealth Group</div>
            <div><strong>Michelle Greene</strong> — Global CIO, Cardinal Health</div>
            <div><strong>BJ Moore</strong> — Former CIO, Providence Healthcare</div>
            <div><strong>Daniel Barchi</strong> — CIO, CommonSpirit</div>
            <div style="color:var(--text3);margin-top:4px">+ 20 CIOs/CTOs across Boeing, Toast, United Airlines, Sephora, PayPal, Hasbro, AIG, and more</div>
          </div>
        </div>
        <div style="background:rgba(255,92,170,.04);border-radius:12px;padding:16px;border:1px solid rgba(255,92,170,.06)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:13px;margin-bottom:8px;color:#FF5CAA">CISO Council <span style="font-weight:400;font-size:11px;color:var(--text3)">(13 members)</span></div>
          <div style="font-size:11px;color:var(--text2);line-height:1.7">
            <div><strong>Aimee Cardwell</strong> — Former EVP & CISO, UnitedHealth Group</div>
            <div><strong>James Beeson</strong> — Former CISO, Cigna</div>
            <div><strong>Nick Vigier</strong> — CISO, Oscar Health</div>
            <div><strong>Aanchal Gupta</strong> — CVP, Microsoft</div>
            <div><strong>Derek Benz</strong> — CISO, Coca-Cola</div>
            <div><strong>Lakshmi Hanspal</strong> — Former Global CISO, Amazon</div>
            <div style="color:var(--text3);margin-top:4px">+ 7 CISOs across EA, CBRE, IHG, CSX, Bill.com, Alteryx, Republic Services</div>
          </div>
        </div>
      </div>

      <div style="display:grid;grid-template-columns:1fr;gap:12px">
        <div style="background:rgba(255,107,157,.04);border-radius:12px;padding:16px;border:1px solid rgba(255,107,157,.06)">
          <div style="font-family:var(--font-g);font-weight:700;font-size:13px;margin-bottom:8px;color:#FF6B9D">Executive Advisors <span style="font-weight:400;font-size:11px;color:var(--text3)">(40+ advisors)</span></div>
          <div style="display:grid;grid-template-columns:1fr 1fr;gap:2px 24px;font-size:11px;color:var(--text2);line-height:1.7">
            <div><strong>Tiffany Inglis</strong> — CMO, Sera Prognostics</div>
            <div><strong>Michelle Carnahan</strong> — President, Thirty Madison</div>
            <div><strong>David Weathington</strong> — VP Network & VBS, Elevance</div>
            <div><strong>Mike Bowersox</strong> — Former Medicare President, Humana</div>
            <div><strong>Jason Parrot</strong> — SVP Enterprise Growth, Vida</div>
            <div><strong>Michael Hoff</strong> — Global Head of Partners, Mistral AI</div>
            <div><strong>Garrett Marker</strong> — CRO, Brex</div>
            <div><strong>Benn Stancil</strong> — Founder & CTO, Mode</div>
            <div style="color:var(--text3);grid-column:1/-1;margin-top:4px">+ 30+ advisors from Stripe, HubSpot, Cloudflare, Meta, monday.com, Grafana, Klaviyo, Warby Parker, and more</div>
          </div>
        </div>
      </div>

    </div>
  </div>

  <!-- THANK YOU / CTA -->
  <div class="content-panel" data-node="end">
    <div class="panel-color-bar" style="background:linear-gradient(90deg,#635BFF,#80E9FF)"></div>
    <div class="panel-inner">
      <div class="panel-breadcrumb"><span>Home</span><span class="bc-sep">›</span><span>Our Team</span><span class="bc-sep">›</span><span style="color:var(--accent)">Thank You</span></div>
      <div class="cta-content">
        <div class="hero-eyebrow" style="justify-content:center;margin-bottom:24px">
          <img src="https://www.stripes.co/dist/svg/logo-black.svg" alt="Stripes" class="brand-logo-lg" onerror="this.outerHTML='<span style=font-weight:800;letter-spacing:.05em>///\\ STRIPES</span>'">
          <span class="x-mark">×</span>
          <span class="iso-logo" style="height:28px">
            <svg class="iso-frame" viewBox="0 0 259 40" xmlns="http://www.w3.org/2000/svg"><path fill="#1E1E1E" d="M258.8,5.6v28.9c0,3.1-2.5,5.6-5.6,5.6h-64.1c-2.2,0-4.1-1.3-5-3.1c-0.9,1.9-2.8,3.1-5,3.1H45.5c-2.2,0-4.1-1.3-5-3.1c-0.9,1.8-2.8,3.1-5,3.1h-30C2.5,40,0,37.5,0,34.4V5.6C0,2.5,2.5,0,5.6,0h30c2.2,0,4.1,1.3,5,3.1c0.9-1.8,2.8-3.1,5-3.1h133.6c2.2,0,4.1,1.3,5,3.1c0.9-1.9,2.8-3.1,5-3.1h64.1C256.3,0,258.8,2.5,258.8,5.6L258.8,5.6zM40,34.4V5.6c0-2.5-2-4.4-4.4-4.4h-30c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.4,2,4.4,4.4,4.4h30C38,38.9,39.9,36.9,40,34.4zM183.6,34.4V5.6c0-2.4-2-4.4-4.4-4.4H45.5c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.5,2,4.4,4.4,4.4h133.6C181.6,38.9,183.6,36.9,183.6,34.4zM257.7,5.6c0-2.4-2-4.4-4.4-4.4h-64.1c-2.4,0-4.4,2-4.4,4.4v28.9c0,2.4,2,4.4,4.4,4.4h64.1c2.4,0,4.4-2,4.4-4.4V5.6z"/><path fill="#1E1E1E" transform="translate(9.065,1.4) scale(0.93)" d="M52.3,28.1h2.5V9.5h-2.5V28.1zM65.9,21.2c-0.3-0.2-0.6-0.3-1-0.4c-0.4-0.1-1.1-0.3-2.3-0.6c-1.3-0.3-1.6-0.4-1.9-0.5c-0.8-0.3-1.1-0.7-1.1-1.4c0-1.2,1-2,2.6-2c1.6,0,3,0.8,3.7,2.2l1.7-1.3c-0.8-1.7-2.9-2.8-5.2-2.8c-1.5,0-2.6,0.4-3.6,1.2c-0.9,0.8-1.4,1.7-1.4,2.9c0,1.2,0.4,2.1,1.5,2.7c0.3,0.2,0.6,0.4,1.1,0.5c0.4,0.1,1.1,0.3,2,0.5c0.8,0.2,1.3,0.3,1.6,0.4c0.2,0.1,0.5,0.1,0.6,0.2c0.9,0.3,1.3,0.8,1.3,1.6c0,1.3-1.2,2.1-3,2.1s-3.4-1-4.1-2.5l-1.8,1.3c1,2,3.3,3.2,6,3.2c1.5,0,2.7-0.4,3.8-1.2c1-0.8,1.5-1.8,1.5-3.1C67.6,22.8,67.1,21.9,65.9,21.2zM80,16.4c1.1,1.2,1.6,3,1.6,4.9s-0.6,3.7-1.6,4.9c-1.1,1.3-2.8,2.1-4.7,2.1c-1.9,0-3.5-0.8-4.7-2.1c-1.1-1.2-1.6-3-1.6-4.9s0.6-3.7,1.6-4.9c1.1-1.3,2.8-2.1,4.7-2.1C77.2,14.3,78.9,15.1,80,16.4zM79.3,21.4c0-3.1-1.6-5.1-3.9-5.1c-2.4,0-3.9,2-3.9,5.1s1.6,5.1,3.9,5.1C77.8,26.4,79.3,24.5,79.3,21.4zM98.2,14.3c-1.8,0-3.4,0.9-4.3,2.3c-0.7-1.5-2-2.3-3.8-2.3c-1.7,0-3.1,0.8-3.9,2.1v-1.8h-2.3v13.5h2.3V20c0-1,0.3-1.8,0.9-2.5c0.6-0.6,1.5-1.1,2.3-1.1c1.7,0,2.7,1.2,2.7,3.3v8.3h2.3V20c0-1,0.3-1.8,0.9-2.5c0.6-0.6,1.5-1.1,2.3-1.1c1.7,0,2.7,1.2,2.7,3.3v8.3h2.3v-8.9C102.6,16.3,100.9,14.3,98.2,14.3zM115.6,16.4c1.1,1.2,1.6,3,1.6,4.9s-0.6,3.7-1.6,4.9c-1.1,1.3-2.8,2.1-4.7,2.1s-3.5-0.8-4.7-2.1c-1.1-1.2-1.6-3-1.6-4.9s0.6-3.7,1.6-4.9c1.1-1.3,2.8-2.1,4.7-2.1S114.5,15.1,115.6,16.4zM114.9,21.4c0-3.1-1.6-5.1-3.9-5.1c-2.4,0-3.9,2-3.9,5.1s1.6,5.1,3.9,5.1C113.4,26.4,114.9,24.5,114.9,21.4zM121.8,16.3v-1.7h-2.3v13.5h2.3v-7.4c0-1.2-0.1-2.5,0.6-3.2c0.5-0.5,0.9-0.6,1.9-0.6c0.4,0,2.1,0,2.1,0v-2.3h-2.2C123.7,14.6,122.4,14.8,121.8,16.3zM139.1,16.5c0.9,1.3,1.5,3,1.5,4.9s-0.5,3.6-1.5,4.9c-1.1,1.4-2.6,2.2-4.4,2.2c-1.8,0-3.4-0.8-4.2-2.3v6.6h-2.3V14.6h2.3v2c0.9-1.4,2.4-2.2,4.2-2.2C136.5,14.3,138.1,15.1,139.1,16.5zM138.2,21.4c0-3-1.5-5-4-5c-2.3,0-3.8,1.7-3.8,4.5v1c0,2.8,1.6,4.5,3.8,4.5C136.7,26.4,138.2,24.4,138.2,21.4zM149.1,14.3c-1.7,0-3.1,0.8-4,2.1V9.5h-2.3v18.6h2.3v-8.1c0-1,0.3-1.9,1-2.5c0.7-0.7,1.5-1,2.4-1c1.8,0,2.8,1.2,2.8,3.3v8.3h2.3v-8.9C153.6,16.2,151.9,14.3,149.1,14.3zM156.4,28.1h2.3V14.6h-2.3V28.1zM156.1,12.6h2.9v-3h-2.9V12.6zM167.4,26.4c-2.5,0-4.1-2-4.1-5s1.6-5,4.1-5c1.7,0,3,1,3.4,2.9l2-1c-0.7-2.4-2.7-3.9-5.4-3.9c-1.9,0-3.6,0.7-4.7,2.1c-1.1,1.3-1.7,3-1.7,5s0.6,3.7,1.7,5c1.1,1.3,2.8,2.1,4.7,2.1c2.7,0,4.7-1.6,5.4-4l-2.1-1C170.3,25.3,169.1,26.4,167.4,26.4zM198.6,9.5h-2.5v18.6h11.8V26h-9.3V9.5zM220.2,26.1h1.2v2h-2.8c-0.7,0-1.2-0.4-1.2-1.5c-0.9,1.1-2.6,1.8-4.4,1.8c-1.3,0-2.4-0.4-3.2-1.1c-0.8-0.7-1.2-1.7-1.2-2.8c0-2.3,1.5-3.7,5.1-4.4l3.3-0.7v-0.6c0-1.6-0.9-2.4-2.7-2.4c-1.7,0-2.7,0.8-3.1,2.3l-2.2-0.6c0.7-2.3,2.7-3.8,5.4-3.8c3.1,0,4.9,1.6,4.9,4.4v6.6C219.3,26,219.2,26.1,220.2,26.1zM217,21.2l-2.6,0.6c-2.6,0.5-3.5,1.3-3.5,2.6c0,1.3,0.9,2.1,2.4,2.1c1,0,1.9-0.3,2.6-0.8c0.7-0.6,1.1-1.3,1.1-2.1V21.2zM233.7,16.5c0.9,1.3,1.5,3,1.5,4.9s-0.5,3.6-1.5,4.9c-1.1,1.4-2.6,2.2-4.4,2.2s-3.4-0.8-4.2-2.3v2h-2.3V9.5h2.3v7c0.9-1.4,2.4-2.2,4.2-2.2C231.1,14.3,232.7,15.1,233.7,16.5zM232.8,21.4c0-3-1.5-5-4-5c-2.3,0-3.8,1.7-3.8,4.5v1c0,2.8,1.6,4.5,3.8,4.5C231.3,26.4,232.8,24.4,232.8,21.4zM245.5,21.2c-0.3-0.2-0.6-0.3-1-0.4c-0.4-0.1-1.1-0.3-2.3-0.6c-1.3-0.3-1.6-0.4-1.9-0.5c-0.8-0.3-1.1-0.7-1.1-1.4c0-1.2,1-2,2.6-2c1.6,0,3,0.8,3.7,2.2l1.7-1.3c-0.8-1.7-2.9-2.8-5.2-2.8c-1.4,0-2.6,0.4-3.6,1.2c-0.9,0.8-1.4,1.7-1.4,2.9c0,1.2,0.4,2.1,1.4,2.7c0.3,0.2,0.6,0.4,1.1,0.5c0.4,0.1,1.1,0.3,2,0.5c0.8,0.2,1.3,0.3,1.6,0.4c0.2,0.1,0.5,0.1,0.6,0.2c0.9,0.3,1.3,0.8,1.3,1.6c0,1.3-1.2,2.1-3,2.1c-1.8,0-3.4-1-4.1-2.5l-1.8,1.3c1,2,3.3,3.2,6,3.2c1.5,0,2.7-0.4,3.8-1.2c1-0.8,1.5-1.8,1.5-3.1C247.1,22.8,246.6,21.9,245.5,21.2z"/></svg>
            <span class="iso-lottie" data-iso-lottie style="width:15.4%;height:100%;border-radius:3px"></span>
          </span>
        </div>
        <h2>Thank You</h2>
        <p>We believe Isomorphic Labs can revolutionize drug discovery. Let's build the future of medicine together.</p>
      </div>
      <div class="cta-footer">
        <span>Stripes × Isomorphic Labs • February 2026</span>
        <span>Confidential — For Discussion Purposes Only</span>
      </div>
    </div>
  </div>

</div>

<!-- ══ CDN DEPENDENCIES ══ -->
<script src="https://cdn.jsdelivr.net/npm/gsap@3.12.7/dist/gsap.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/lottie-web/5.12.2/lottie.min.js"></script>

<script>
// ═══════════════════════════
// PASSWORD GATE
// ═══════════════════════════
(function(){
  const PASS = 'StripesLovesIsomorphic';
  const gate = document.getElementById('pw-gate');
  const inp = document.getElementById('pw-input');
  const btn = document.getElementById('pw-btn');
  if(sessionStorage.getItem('pw-ok')==='1'){ gate.classList.add('unlocked'); }
  function tryUnlock(){
    if(inp.value === PASS){
      sessionStorage.setItem('pw-ok','1');
      gate.classList.add('unlocked');
      // Replay all Lottie logos after gate fades
      setTimeout(function(){
        if(window.isoLottieInstances){
          window.isoLottieInstances.forEach(function(inst){ inst.anim.goToAndPlay(0, true); });
        }
      }, 800);
    } else {
      inp.classList.add('pw-error');
      inp.value = '';
      inp.placeholder = 'Incorrect password';
      setTimeout(()=>{ inp.classList.remove('pw-error'); inp.placeholder='Password'; },800);
    }
  }
  btn.addEventListener('click', tryUnlock);
  inp.addEventListener('keydown', e=>{ if(e.key==='Enter') tryUnlock(); });
})();

// ═══════════════════════════
// NODE DATA (for cluster nav)
// ═══════════════════════════
const nodeData = [
  { id:'hero', label:'Cover', cluster:'Introduction', color:'#635BFF' },
  { id:'investments', label:'Recent Investments', cluster:'Introduction', color:'#80E9FF' },
  { id:'rdcrisis', label:'R&D Productivity Crisis', cluster:'Industry Landscape', color:'#E85D75' },
  { id:'trialheadwinds', label:'Clinical Trial Headwinds', cluster:'Industry Landscape', color:'#FF7A00' },
  { id:'aivalue', label:'AI Across Pharma', cluster:'Industry Landscape', color:'#635BFF' },
  { id:'rdparadigms', label:'R&D Paradigms', cluster:'Industry Landscape', color:'#80E9FF' },
  { id:'inflection', label:'Pharma Inflection', cluster:'Our Perspective', color:'#FF4D6D' },
  { id:'diligence', label:'Market Diligence', cluster:'Our Perspective', color:'#24D164' },
  { id:'thesis', label:'Investment Thesis', cluster:'Our Perspective', color:'#635BFF' },
  { id:'uvp', label:'Unique Value Prop', cluster:'Our Perspective', color:'#80E9FF' },
  { id:'validation', label:'Partner Case Study', cluster:'Our Perspective', color:'#E21937' },
  { id:'competitive', label:'Competitive Landscape', cluster:'Our Perspective', color:'#FF5CAA' },
  { id:'growth', label:'Growth Vectors', cluster:'Our Perspective', color:'#24D164' },
  { id:'risks', label:'Risks & Mitigants', cluster:'Our Perspective', color:'#FF7A00' },
  { id:'team', label:'Stripes Overview', cluster:'Our Team', color:'#635BFF' },
  { id:'scaleteam', label:'Scale Team', cluster:'Our Team', color:'#24D164' },
  { id:'healthcare', label:'Healthcare Expertise', cluster:'Our Team', color:'#FF6B9D' },
  { id:'ops', label:'Our Network', cluster:'Our Team', color:'#80E9FF' },
  { id:'end', label:'Thank You', cluster:'Our Team', color:'#635BFF' },
];

// ═══════════════════════════
// STATE
// ═══════════════════════════
let appState = 'home'; // 'home' | 'content'
let activeNodeId = null;
function getIsMobile() { return window.matchMedia('(max-width:768px)').matches; }

// ═══════════════════════════
// DOM REFERENCES
// ═══════════════════════════
const sceneContainer = document.getElementById('scene-container');
const deckNav = document.getElementById('deckNav');
const backBtn = document.getElementById('backBtn');
const clusterNav = document.getElementById('clusterNav');
const brandOverlay = document.getElementById('brandOverlay');

// ═══════════════════════════
// NAVIGATION OVERLAY LOGIC
// ═══════════════════════════
window.toggleNavSection = function(titleEl) {
  const section = titleEl.closest('.nav-section');
  // Accordion: close all others, toggle clicked — works in both home and sidebar mode
  const isExpanded = section.classList.contains('expanded');
  deckNav.querySelectorAll('.nav-section.expanded').forEach(s => s.classList.remove('expanded'));
  if (!isExpanded) section.classList.add('expanded');
  // In sidebar mode, also navigate to the first item of the opened section
  if (!isExpanded && deckNav.classList.contains('sidebar')) {
    const firstItem = section.querySelector('.nav-item');
    if (firstItem && firstItem.dataset.target) {
      switchPanel(firstItem.dataset.target);
    }
  }
};

// Nav item click → open content panel
document.querySelectorAll('.nav-item').forEach(btn => {
  btn.addEventListener('click', () => {
    const target = btn.dataset.target;
    if (target) openPanel(target);
  });
});

// ═══════════════════════════
// OPEN PANEL
// ═══════════════════════════
function openPanel(nodeId) {
  // If already viewing a panel, just switch
  if (appState === 'content') {
    switchPanel(nodeId);
    return;
  }

  appState = 'content';
  activeNodeId = nodeId;

  // Subtle video overlay shift
  sceneContainer.classList.add('panel-open');

  // On mobile, pause video to save battery
  if (getIsMobile()) { try { bgVideo.pause(); } catch(e) {} }

  // Slide nav to sidebar position (hides fully on mobile via CSS)
  deckNav.classList.add('sidebar');

  // Show back button
  backBtn.classList.add('visible');

  // Build cluster nav
  buildClusterNav(nodeId);

  // Show the panel
  showPanel(nodeId);
}

// ═══════════════════════════
// CLOSE PANEL (back to home)
// ═══════════════════════════
window.closePanel = function() {
  if (appState !== 'content') return;

  hidePanel(activeNodeId);
  appState = 'home';
  activeNodeId = null;

  // Restore video overlay
  sceneContainer.classList.remove('panel-open');

  // On mobile, resume video playback
  if (getIsMobile()) { try { bgVideo.play().catch(() => {}); } catch(e) {} }

  // Return nav to center (restores on mobile via CSS)
  deckNav.classList.remove('sidebar');

  // Hide back button & cluster nav
  backBtn.classList.remove('visible');
  clusterNav.classList.remove('visible');
  clusterNav.innerHTML = '';
};

// ═══════════════════════════
// CONTENT PANEL SHOW/HIDE
// ═══════════════════════════
function showPanel(nodeId) {
  const panel = document.querySelector(`.content-panel[data-node="${nodeId}"]`);
  if (!panel) return;
  panel.scrollTop = 0;
  panel.classList.add('active');

  // Stagger entrance of panel inner children
  const children = panel.querySelectorAll('.panel-inner > *');
  children.forEach((child, i) => {
    child.style.opacity = '0';
    child.style.transform = 'translateY(16px)';
    setTimeout(() => {
      child.style.transition = 'opacity .45s cubic-bezier(.22,1,.36,1), transform .45s cubic-bezier(.22,1,.36,1)';
      child.style.opacity = '1';
      child.style.transform = 'translateY(0)';
    }, 100 + i * 60);
  });

  setTimeout(() => animateCounters(panel), 200);
  setTimeout(() => animateMiniBars(panel), 300);
  setTimeout(() => animateTimeline(panel), 400);
}

function hidePanel(nodeId) {
  const panel = document.querySelector(`.content-panel[data-node="${nodeId}"]`);
  if (!panel) return;
  panel.classList.remove('active');
  // Reset child styles for next open
  panel.querySelectorAll('.panel-inner > *').forEach(child => {
    child.style.opacity = '';
    child.style.transform = '';
    child.style.transition = '';
  });
}

// ═══════════════════════════
// SWITCH PANEL (within content view)
// ═══════════════════════════
function switchPanel(newNodeId) {
  if (newNodeId === activeNodeId) return;

  hidePanel(activeNodeId);
  activeNodeId = newNodeId;
  showPanel(newNodeId);
  buildClusterNav(newNodeId);
}

// ═══════════════════════════
// CLUSTER NAV (right side dots)
// ═══════════════════════════
function buildClusterNav(activeId) {
  const activeNode = nodeData.find(n => n.id === activeId);
  if (!activeNode) return;

  const cluster = activeNode.cluster;
  const clusterNodes = nodeData.filter(n => n.cluster === cluster);
  clusterNav.innerHTML = '';

  clusterNodes.forEach(n => {
    const dot = document.createElement('div');
    dot.className = 'cluster-nav-dot' + (n.id === activeId ? ' active' : '');
    dot.style.background = n.color;
    dot.style.position = 'relative';
    dot.innerHTML = `<div class="cn-tip">${n.label}</div>`;
    dot.onclick = () => {
      if (n.id !== activeNodeId) {
        hidePanel(activeNodeId);
        activeNodeId = n.id;
        showPanel(n.id);
        buildClusterNav(n.id);
      }
    };
    clusterNav.appendChild(dot);
  });

  clusterNav.classList.add('visible');
}

// ═══════════════════════════
// ANIMATED COUNTERS
// ═══════════════════════════
function animateCounters(panel) {
  const counters = panel.querySelectorAll('[data-count]');
  counters.forEach(el => {
    const target = parseFloat(el.dataset.count);
    const prefix = el.dataset.prefix || '';
    const suffix = el.dataset.suffix || '';
    const decimals = parseInt(el.dataset.decimals || '0');
    const obj = { val: 0 };
    gsap.to(obj, {
      val: target,
      duration: 1.5,
      ease: 'power2.out',
      onUpdate: () => {
        el.textContent = prefix + obj.val.toFixed(decimals) + suffix;
      }
    });
  });
}

// ═══════════════════════════
// MINI BAR CHARTS
// ═══════════════════════════
function animateMiniBars(panel) {
  const bars = panel.querySelectorAll('.mini-bar-fill');
  bars.forEach(bar => {
    const width = bar.dataset.width || '0%';
    gsap.to(bar, { width: width, duration: 1.2, ease: 'power2.out', delay: 0.3 });
  });
}

// ═══════════════════════════
// TIMELINE ANIMATION
// ═══════════════════════════
function animateTimeline(panel) {
  const items = panel.querySelectorAll('.timeline-item');
  items.forEach((item, i) => {
    setTimeout(() => item.classList.add('tl-visible'), 200 + i * 200);
  });
}

// ═══════════════════════════
// EXPANDABLE CARDS
// ═══════════════════════════
window.toggleExpand = function(el) {
  const isExpanded = el.classList.contains('expanded');
  const parent = el.parentElement;
  if (parent) {
    parent.querySelectorAll('.expanded').forEach(sib => {
      if (sib !== el) sib.classList.remove('expanded');
    });
  }
  el.classList.toggle('expanded', !isExpanded);
};

// ═══════════════════════════
// KEYBOARD NAV
// ═══════════════════════════
window.addEventListener('keydown', (e) => {
  if (e.key === 'Escape' && appState === 'content') {
    closePanel();
  }
});

// ═══════════════════════════
// VIDEO BACKGROUND SETUP
// ═══════════════════════════
const bgVideo = document.getElementById('bgVideo');
bgVideo.src = 'home_hero.webm';
bgVideo.load();
bgVideo.play().catch(() => {});

// Fallback: if local fails, try remote
bgVideo.addEventListener('error', function fallback() {
  bgVideo.removeEventListener('error', fallback);
  bgVideo.src = 'https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/videos/home/home_hero.webm';
  bgVideo.load();
  bgVideo.play().catch(() => {});
}, true);

// ═══════════════════════════
// CLICK OUTSIDE TO CLOSE
// ═══════════════════════════
document.getElementById('video-overlay').addEventListener('click', () => {
  if (appState === 'content') closePanel();
});

// ═══════════════════════════
// LOADING SCREEN
// ═══════════════════════════
const loaderStart = Date.now();
const LOADER_MIN_MS = 10000;
function dismissLoader() {
  const elapsed = Date.now() - loaderStart;
  const remaining = Math.max(0, LOADER_MIN_MS - elapsed);
  setTimeout(() => {
    document.getElementById('loader').classList.add('done');
    bgVideo.play().catch(() => {});
  }, remaining);
}
bgVideo.addEventListener('canplaythrough', dismissLoader, { once: true });
setTimeout(dismissLoader, LOADER_MIN_MS);

// ═══════════════════════════
// ANIMATED ISOMORPHIC LOGO (Lottie)
// ═══════════════════════════
const ISO_LOTTIE_URL = 'https://cdn.prod.website-files.com/63692b9f2544be26f383691c/638dc2f2c52f540707527ef9_ISO_logo.json';
window.isoLottieInstances = [];
const isoLottieInstances = window.isoLottieInstances;

document.querySelectorAll('[data-iso-lottie]').forEach(container => {
  const isInPwGate = !!container.closest('#pw-gate');
  const anim = lottie.loadAnimation({
    container: container,
    renderer: 'svg',
    loop: isInPwGate,
    autoplay: isInPwGate,
    path: ISO_LOTTIE_URL
  });
  isoLottieInstances.push({ anim, container });

  // Play animation on hover (replay from start)
  const hoverTarget = container.closest('.brand-overlay') || container.closest('#pw-gate') || container.closest('.hero-eyebrow') || container;
  hoverTarget.addEventListener('mouseenter', () => {
    anim.goToAndPlay(0, true);
  });
});

// Play all on page load after loader finishes
setTimeout(() => {
  isoLottieInstances.forEach(({ anim }) => anim.goToAndPlay(0, true));
}, 11500);

// Replay brand overlay logo when transitioning between home/content
const origOpenPanel = openPanel;
openPanel = function(nodeId) {
  origOpenPanel(nodeId);
  isoLottieInstances.forEach(({ anim }) => anim.goToAndPlay(0, true));
};
const origClosePanel = closePanel;
closePanel = function() {
  origClosePanel();
  isoLottieInstances.forEach(({ anim }) => anim.goToAndPlay(0, true));
};
</script>
</body>
</html>
